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Abstract 
 
Tenascin-C (TN-C) is a component of the extracellular matrix (ECM) and member of 
the matricellular protein family. Matricellular proteins have a special role to influence 
cellular function and matrix composition. Those proteins bind to cellular receptors, 
modulate gene expression and regulate activity of various growth factors, cytokines, 
and proteinases. Therefore, composition of the ECM is a very dynamic network. TN-
C plays an important role during embryonic development in numerous organs, e.g. in 
the heart. In the adult, healthy organism TN-C expression is highly restricted to a few 
regions, such as myotendinous junctions, gut, skin and lymphopoietic organs. Under 
pathological conditions, such as tumour formation, wound healing, infection, 
inflammation, atherosclerosis, mechanical stress, and during tissue remodelling TN-
C expression is up-regulated once again. 
In healthy, adult myocardial tissue TN-C is not expressed but up-regulation starts 
under pathological conditions, such as myocardial infarction (MI), myocarditis, and 
dilated cardiomyopathy. After MI TN-C is mainly expressed by fibroblasts and up-
regulated in the border zone between infarcted and non-infarcted region of the left 
ventricle within 24 hours. 
TN-C plays a dual role in cardiac healing post MI: On one hand, TN-C is important in 
loosen strong adhesion of cardiomyocytes and helps to rearrange surviving cells in 
the infarcted region. Myofibroblasts were recruited and production of matrix 
components is stimulated to strengthening the cardiac matrix. The elastic properties 
of TN-C may also help to resist the increased mechanical loading to which the border 
zone of the infarct is subjected. On the other hand, TN-C may loosen cardiomyocytes 
from the ECM, causing slippage of cardiomyocytes and supports invasion of 
inflammatory cells. Additionally TN-C up-regulates matrix metalloproteinases 
(MMPs), promotes ECM degradation and loosen cardiac tissue, which leads to an 
increasing risk of wall thinning, cardiac dilatation and left ventricle rupture. 
 
The aim of this thesis was to investigate TN-C regulation post MI and to study the 
temporal and spatial expression pattern in an experimental MI animal model. Eight 
time points during the early phase post infarction (0.5, 1, 2, 3, 5, 7, 10, and 14 days 
post MI) were analysed and compared to a sham operated control group. At each 
time point samples were collected for histological and molecular biological analysis 
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(real time-PCR, PCR, western blot and sequencing). First, the complete, until now 
unknown, rat cDNA TN-C sequence (GenBank, EU596506) encompassing an open 
reading frame of 6.057bp was sequenced. The experiments showed that different 
TN-C isoforms were up-regulated at different time points post MI. Those isoforms 
differ in size, because of alternative splicing processes within the fibronectin type III 
(FN-III) domain. Overall a time dependent isoform shift could be shown and 4 
different isoforms, with none, 1, 2, and 5 FN-III domains, which are up-regulated post 
MI were identified. 
Small TN-C (TN-CS) isoforms, which exhibit none or only a few FN-III domains in the 
alternative spliced side, are present within `normal´ and healthy ECM. In contrast, 
large TN-C (TN-CL) isoforms are up-regulated under pathologic conditions. 
Those facts suggest that the function of different spliced TN-C isoforms can be 
regulated through a time dependent shift during tissue remodelling processes post 
MI.  
 
 
Keywords: tenascin C, myocardial infarction, remodelling, fibroblasts, alternative 
splicing, isoforms 
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Zusammenfassung 
 
Das Protein Tenascin-C (TN-C) ist Bestandteil der extrazellulären Matrix (EZM) und 
gehört zur Familie der matrizellulären Proteine. Matrizelluläre Proteine beeinflussen 
wichtige Zellfunktionen und den Aufbau der EZM. Sie binden an zelluläre 
Rezeptoren, modulieren die Genexpression und regulieren die Aktivität von 
verschiedenen Wachstumsfaktoren, Zytokinen und Proteinasen. Die EZM stellt somit 
ein sehr dynamisches Netzwerk dar. Während der Embryonalentwicklung spielt TN-C 
in vielen Geweben, wie zum Beispiel dem Herzen, eine wichtige Rolle. Im adulten, 
gesunden Organismus wird TN-C nur sehr lokal, wie etwa in den myotendinous 
junctions, dem Darm, der Haut und lymphatischen Organen exprimiert. Unter 
pathologischen Bedingungen wie z.B. bei Tumorentstehung, Wundheilung, Infektion, 
Inflammation, Atherosklerose, mechanischem Stress und dem Remodelling Prozess 
kommt es erneut zu einer Hochregulation von TN-C.  
Während im adulten, gesunden Herzen das Protein nicht exprimiert wird, kommt es 
unter pathologischen Umständen, wie Myokardinfarkt (MI), Myokarditis oder 
dilatativer Kardiomyopathie, erneut zur Proteinexpression. Nach einem 
Myokardinfarkt ist TN-C in der Randzone zwischen infarziertem und nicht 
infarziertem Gewebe innerhalb von 24 Stunden detektierbar, wobei die Hauptquelle 
der TN-C Produktion die Fibroblasten darstellen. 
TN-C spielt eine duale Rolle im kardialen Wundheilungsprozess: Auf der einen Seite 
kommt es durch Deadhäsion der Kardiomyozyten zu einer Umstrukturierung des 
infarzierten Gewebes. Myofibroblasten können leicht in das betroffene Areal 
einwandern und Matrixkomponenten für die Stärkung der EZM produzieren. Zudem 
wirkt TN-C mit seiner Elastizität der enormen mechanischen Last, die auf die 
Randzone des Infarktareals wirkt, entgegen. Auf der anderen Seite können 
Kardiomyozyten von der EZM abrutschen und inflammatorische Zellen einwandern. 
Matrixmetalloproteinasen (MMPs) werden verstärkt exprimiert, was zur Degradation 
der EZM führt. Dadurch kann es zu einer Ausdünnung des linken Ventrikels, einer 
Dilatation und im schlimmsten Fall zur Ruptur des Ventrikels kommen. 
 
Im Rahmen der vorliegenden Arbeit liegt das Hauptinteresse auf dem zeitlichen und 
räumlichen TN-C Expressionsmuster nach einem Myokardinfarkt, welches am 
Rattenmodell untersucht wurde. Insgesamt wurden acht verschiedene Zeitpunkte 
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(0.5, 1, 2, 3, 5, 7, 10 und 14 Tage) nach Infarkt untersucht, und mit einer sham 
operierten Kontrollgruppe verglichen. Zu jedem Zeitpunkt wurden Proben für  
histologische und molekularbiologische Analysen (Real time-PCR, PCR, Western 
Blot und Sequenzierungen) entnommen. Zuerst wurde die gesamte, bisher 
unbekannte, TN-C cDNA Ratten-Sequenz mit 6.057bp (GenBank, EU596506) 
sequenziert. Die Untersuchungen zeigten, dass verschiedene TN-C Isoformen zu 
unterschiedlichen Zeitpunkten post MI vorhanden sind. Diese Isoformen kommen 
durch alternatives Splicing der Fibronektin Typ-III Domänen (FN-III) zustande. Es 
wurde ein zeitlicher Shift der Isoformen nachgewiesen und insgesamt 4 
verschiedene Isoformen, mit keiner, 1, 2 und 5 FN-III Domänen identifiziert. 
Es ist bekannt, dass Isoformen mit wenigen bzw. keinen FN-III in der alternativ 
gesplicten Region mit einer gesunden und „normalen“ EZM korrelieren, während 
größere Varianten mit vielen FN-III Domänen, mit pathologischen Veränderungen im 
Zusammenhang stehen.  
Aus diesen Fakten kann man schließen, dass die Funktion der unterschiedlich 
gesplicten TN-C Isoformen durch einen zeitlichen Shift nach einem MI reguliert wird.  
 
 
Schlagworte: Tenascin C, Myokardinfarkt, Remodelling, Fibroblasten, Alternatives 
Splicen, Isoformen 
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1. INTRODUCTION  
 
 
1.1. The Extracellular Matrix - Matricellular Proteins 
 
Specialised cells of developing multicellular organisms are embedded in a complex 
extracellular matrix (ECM). The ECM regulates the dynamic cell environment and 
affects cellular processes including cell growth, differentiation, migration, survival as 
well as wound healing and fibrosis. 
Major components of the ECM are different types of collagens, proteoglycans, and 
glycoproteins, which are produced intracellular by resident cells, secreted outside the 
cells and assimilate into the existent ECM. Additionally the ECM contains many 
growth factors, cytokines, proteinases, and a lot of other bioactive molecules that 
interact with the cell surface [1]. 
Therefore, the complex composition of the ECM serves many functions, such as 
cellular anchorage, intercellular communication, and flexibility of mature tissues. 
 
During the last 15-20 years, increasing attention turned to matrix proteins, which 
modulate cell function but do not appear to have a direct structural role within the 
ECM. These proteins have been termed matricellular proteins to accentuate their 
special role to influence cell function. Matricellular proteins regulate cellular function 
and matrix composition by binding to their cellular receptors and by modulating 
expression and activity of growth factors, cytokines, and proteinases [1, 2].  
In cardiac tissue, matricellular proteins include, thrombospondin-1 (TSP1), 
thrombospondin-2 (TSP2), osteonectin (also known as BM-40 or SPARC = secreted 
protein acidic and rich in cystein), osteopontin (OPN), tenascin-X (TN-X), and in 
particular tenascin-C (TN-C) [3]. 
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1.2. The Tenascin Family 
 
The tenascin (TN) family includes five proteins (shown in Figure 1.): TN-C, TN-R, TN-
X, TN-Y and TN-W [4, 5]. 
TN protein expression appears highly restricted and shows dynamic pattern during 
embryonic development, particularly during neural development, organogenesis, 
skeletogenesis, and vasculogenesis. However, each TN exhibits a specific 
expression pattern and localisation of expression overlap only in parts. 
 
 
 
 
Figure 1. Schematic diagram of all members of the tenascin family (TA domain = 
tenascin assembly domain, EGF-L repeats = epidermal growth factor like repeats, 
FN-III domains = fibronectin type III domains, FG = fibrinogen globe) [5]. 
 
 
1.2.1. Tenascin-C 
 
The hexameric protein TN-C (shown in Figure 2.) was discovered simultaneously in a 
number of laboratories in the early 1980s. 
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The name `tenascin´ originated from the ability as adhesion protein (from the latin 
`tenere´ = to hold) and its known association to a variety of `nascent´ tissues (`nacsi´ 
= to be born) [6, 7].  
The protein was first called TN-C in 1986 by Chiquet-Ehrismann et al. [6], but in the 
last twenty years TN-C was given a number of different names including: 
glial/mesenchymal extracellular matrix protein (GMEM) [8], myotendinous antigen [9, 
10], hexabrachion [11], cytotactin [12], J1 220/200 [13], tenascin [6], and neuronectin 
[14]. After detecting other proteins belonging to the TN family, the `C´ from TN-C 
reminds of cytotactin - one of the first names of the protein. 
 
 
 
 
Figure 2. (A) Image of two mouse TN-C molecules. Each arm is approximately 
100nm in length. (B) Schematic model of hexameric TN-C structure (EGF-L repeats  
= epidermal growth factor like repeats, FN-III domains = fibronectin type III domains) 
[5]. 
 
 
In 1984 Chiquet-Ehrismann et al. described a monoclonal antibody M1 called 
`myotendinous antigen´ [9, 10], which recognises an ECM component expressed in 
myotendinous junctions, within the perichondrium during early chicken 
embryogenesis and in developing ligaments and tendons. In 1986 Chiquet-
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Ehrismann et al. renamed this protein as TN-C. It was demonstrated that TN-C is 
selectively present within the mesenchyme, surrounding fetal rat mammary glands, 
hair follicles, teeth, three organ anlagen, and additionally associated with mammary 
tumours [6].  
From 1986 to 1988 Erickson and Taylor [15], Hoffmann et al. [16] and Chiquet-
Ehrismann et al. [6] postulated simultaneously that TN-C is identical to the GMEM 
defined by a monoclonal antibody which was described in 1983 [8]. The 1984 
characterised protein hexabrachion [11] and the 1985 descript molecule cytotactin 
[12], were also identical with TN-C. Furthermore, the J1-antigen descript in 1985 [13] 
showed homologies to TN-C. 
 
Particularly, selectively TN-C up-regulation in epithelial-mesenchymal junction in 
embryonic development produced interest. 
In 1988 it was demonstrated in mesenchyme from small intestine, where reciprocal 
mesenchymal-epithelial interaction is known to be important for gut morphogenesis, 
that the appearance of TN-C in the mesenchyme was dependent on the presence of 
epithelium [17]. 
 
 
1.2.1.1. Expression of Tenascin-C 
 
In adults, TN-C expression is normally restricted to a few areas. TN-C is found in 
musculoskeletal regions in which high mechanical forces are transmitted from one 
tissue component to another, for example from muscle to tendon and from tendon to 
bone [18]. Furthermore, TN-C is present interstitially in a variety of tissues such as 
parts of the brain, gut, skin, and lymphopoietic organs [19].   
 
However, under specific pathological conditions such as inflammation, wound healing 
and tumourgenesis, TN-C re-expression is observed [7]. Especially in tumour tissue 
TN-C is extremely up-regulated [19]. 
TN-C expression can be induced by a variety of pro- and anti-inflammatory cytokines 
and interleukins such as IL-1/4/6/8/13, tumour necrosis factor α (TNF-α), interferon γ 
(IFN-γ), and growth factors such as epidermal growth factor (EGF), transforming 
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growth factor β (TGF-β), connective tissue growth factor (CTGF), platelet-derived 
growth factor-BB (PDGF-BB), Lif-1, and NfκB (nuclear factor kappa-light-chain-
enhancer of activated B cells) [14, 20, 21]. In addition, hypoxia, reactive oxygen 
species (ROS), and mechanical stress, which plays an essential role in tumour 
tissue, also induce TN-C expression [22].  
Ras protein/MAPK (rat sarcoma protein/mitogen-activated protein kinase) and Wnt 
can result in TN-C expression and, interestingly, both of these signalling pathways 
are induced by TN-C. This mechanism suggests a positive feedback regulation of 
TN-C expression and responses to TN-C in tumours [22].  
Activation of reporter constructs under control of the human TN-C promoter suggests 
that signalling leads to activation of a cascade of prominent transcription factors. 
Those factors, involved in activation of TN-C gene transcription, include TCF/LEF (T- 
cell-specific transcription factor/lymphoid enhancer-binding factor), NfκB, c-Jun, Ets, 
Sp1, and Prx-1 [22-24]. 
 
A variety of molecules have been identified as receptors for TN-C include members 
of the integrin family, contactin/F11, which is a cell adhesion molecule belonging to 
the immunoglobulin superfamily, annexin II, a receptor tyrosine phosphatase, and 
cell surface heparan sulfate proteoglycans [7, 25]. 
 
It is noticeable that TN-C expression is so tightly controlled in normal and healthy 
tissue homeostasis, because of the high number of factors that induce TN-C 
expression. 
 
 
1.2.1.2. Degradation of Tenascin-C 
 
TN-C is degraded by members of the matrix metalloproteinases (MMP) family in 
numerous of tissues [7]. TN-C deposition coincides with the expression and activity 
of matrix MMPs and, furthermore, MMPs and TN-C are regulated by a reciprocal 
mechanism [5].  
 
In healthy adult cardiac tissue different MMPs, including collagenases (MMP-1, 
MMP-13, and MMP-8), gelatinases (MMP-2 and MMP-9), stromelysins (MMP-3 and 
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MMP-7) and membrane-type MMPs (MMP-14) are expressed.  
Additional all 4 tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2, TIMP-
3 and TIMP-4) have been identified within the normal human myocardium [26]. 
 
Within the heart it has been shown that MMP distribution may be also `chamber 
specific´. For example, the relative level of MMP-1 is lower in the right ventricle 
compared to the left ventricle. 
This chamber specific MMP appearance results from a combination of factors 
including different loading conditions, embryological origin, and cellular response to 
biological stimuli [26]. 
 
Studies with rat and mouse MI models as well as tissue samples from patients 
undergoing emergent cardiac surgery showed mainly increased levels of MMP-2 and 
MMP-9 [26]. 
Expression of MMPs lead to a reorganisation of pre-existing ECM and provide a 
modified tissue microenvironment, promoting cell migration, growth, survival, and 
differentiation [5]. 
 
TN-C is known to induce MMP expression, for example large TN-C isoforms, with 
many FN-III domains in the splicing region, up-regulate MMP-1 through a MAPK 
pathway in human chondrosarcoma cells [27].  
Small TN-C isoforms, with none or only a few FN-III domains, can be cleaved 
enzymatic by MMP-7 by removing the NH2-terminal knob. The large isoform shows 
the same MMP-7 sensitive site, but is further degraded in the splicing area by MMP-2 
and MMP-3 [28, 29]. However, the sole site susceptible to proteolytic cleavage by 
MMP-2 and MMP-3 is found within the FN-III A3 domain (Figure 1.). Therefore, small 
TN variants are resistant to MMP-2 and MMP-3 degradation and large isoforms are 
susceptible to this digestion. It seems to be that all TN-C isoforms are resistant to 
MMP-9 [28, 29]. 
 
Alteration in amount and relative level of MMPs and TIMPs results in a modified 
composition of the myocardial matrix. This change affects the overall heart structure, 
geometry, and function [30].  
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1.2.2. Tenascin-R 
 
Tenascin-R (TN-R) also called restrictin, janusin or J1160/180, is - in contrast to TN-C - 
a trimeric molecule and exclusively synthesised within the central nervous system 
(CNS), where it is mainly produced by oligodendrocytes. It is a major component of 
brain ECM during development and persists in the adult organism only in some 
regions of CNS [31].  
 
 
1.2.3. Tenascin-X 
 
Tenascin-X (TN-X) was discovered, because of its opposite overlapping orientation 
with the 21-hydroxylase gene (CYP21B), located in the central region of human 
major histocompatibility complex-III (MHC) locus [32, 33].  
TN-X is widely expressed during embryogenesis, but also persists after birth in 
adults. Fibroblasts are the major source of expression within connective tissue of the 
myocard, skeletal muscle as well as in the dermis of skin [12,13].  
Interestingly, TN-X distribution is distinct and often reciprocal to that of TN-C, for 
instance in embryonic day 15.5 (E15.5) mouse skin and digestive tract, especially 
oesophagus, gut, and stomach [34]. 
 
TN-X is the first member of the TN-family whose deficiency has been clearly 
associated with a pathological disorder in humans called Ehler-Danlos Syndrome 
(EDS). This connective tissue disorder is affecting 1 in 5.000 individuals and is 
associated with fibrillar collagen defects causing a connective tissue disorder 
involving skin and joint hyperflexibility, vascular fragility, and poor wound healing [35]. 
In most patients, bruising has been a prominent feature. In mice inactivation of the 
TN-X gene caused a syndrome similar to the EDS in human [3, 36]. 
 
 
1.2.4. Tenascin-Y 
 
Tenascin-Y (TN-Y) is a protein expressed in chicken and most closely related to 
mammalian TN-X. Both, TN-Y and TN-X, belong to the largest proteins of TN family 
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and are predominantly expressed in cardiac tissue and skeletal muscle, where they 
are up-regulated in muscle-associated connective tissues [37, 38]. 
TN-Y expressed in skin shows a complementary expression pattern to TN-C, 
whereas within the lung and kidney the sites of expression are partly overlapping. 
TN-Y is also present in embryonic skeletal muscle, where it is expressed in 
developing connective tissue between muscle fibres [37]. 
 
 
1.2.5. Tenascin-W 
 
The youngest and smallest member of the TN family is, tenascin-W (TN-W), which 
was first described in 1998 by Weber et al. in zebrafish [39]. In 2004 Scherberich et 
al. described the murine orthologue of zebrafish TN-W [40]. TN-W is expressed 
prominently during palate formation, osteogenesis and smooth muscle development. 
In the adult organism, TN-W is found within the kidney, cardiac semilunar valves, 
corneal limbus and periosteum. Expression pattern showed often a co-localisation 
with TN-C during several early developmental stages [40]. 
 
 
1.3. Structure of Tenascins 
 
All TNs include a common set of structural motives and has been shown to be highly 
elastic. Proceeding in carboxyl terminal direction, the domains (shown in Figure 3.) 
are stringed as follows:  
• the tenascin assembly (TA) domain (shown in green),  
• a linear array of epidermal growth factor-like (EGF-L) repeats (pink domains),  
• two different types of fibronectin type III (FN-III) domains: conserved domains 
in all variants of TN-C (shown in blue) and domains that are alternatively 
spliced (red domains), and finally 
• the carboxyl terminal fibrinogen globe (FG, yellow circle) [5]. 
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Figure 3. Schematic diagram of TN-C structure (TA domain = tenascin assembly 
domain, EGF-L repeats = epidermal growth factor like repeats, FN-III domains = 
fibronectin type III domains, FG = fibrinogen globe) [5]. 
 
 
Even if the structural motives are similar in all five known TNs, domain composition 
differs quite a lot. TN structure composition also varies among different species. 
Human and mouse TN-C contains 14½ EGF-L repeats whereas in chicken TN-C only 
13½ domains exist [41]. One common feature is the terminal fibrinogen globe, which 
equals in all TNs. TN-C, TN-R, and TN-W contain at the amino terminal cysteine 
residues (green triangles) that may allow these molecules to form oligomers, like 
trimers, hexamers or nonamers (shown in Figure 1.). In contrast, TN-X and TN-Y 
appear to lack these residues (white circles) required to stabilise the linkage of 
trimers to form oligomers [5]. 
 
Human TN-C consists of 14½ EGF-L repeats and 17 FN-III domains, 8 constant 
expressed domains and between the fifth and sixth constant domain, 9 domains 
where alternative splicing occurs, named A1, A2, A3, A4, B, AD2, AD1, C, and D 
(Figure 3.). The AD of the AD1 and AD2 stands for additional domains.  
In contrast, mouse (A1, A2, A4, B, C, and D) and chicken (A, B, AD2, AD1, C, and D) 
TN-C only has up to six domains in the splicing region [31]. TN-C sequence motives 
in different species display a high degree of homology, which reaches 95% for 
analogous FN-III domains. 
TN-C covers six polypeptide chains (shown in Figure 2.), which are linked at their 
amino termini via TA domain [5, 42]. Assembly of this hexamer structure is a co-
translational two-step process [31]: In the first step trimer formation is initiated by 
three single monomers linked together to form a triple-stranded coiled coil. In the 
second step, two TN-C trimers join to form a hexamer, which is stabilised by disulfide 
bonds between cysteine-residues in the subunits [43].  
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TN-R includes 4½ EGF-L repeats and either 8 or 9 FN-III repeats. The extra FN-III 
domain (R domain) is alternatively spliced comparable with TN-C [5]. 
 
TN-W shows the same composition of typical modules like all other members of the 
TN family, but no TN contains as few of them as TN-W: 3½ EGF-L repeats and 5 FN-
III domains (WA-WD) in zebrafish. Mouse TN-W contains 9 FN-III repeats instead of 
5 in the zebrafish orthologous [40]. Isoforms from alternative spliced molecules have 
not been reported for zebrafish TN-W.  
 
The largest protein, TN-X, contains 18½ EGF-L repeats and at least 33 FN-III 
repeats. The FN-III repeats in TN-X fall into three different categories, which are 
related to another: X1-21 repeats that have not been shown to undergo alternative 
splicing. XA repeats, near the amino-terminal end of the array that are more related 
to one another and the XR1-XR10 alternatively spliced region [5]. 
Additionally, TN-X contains an unusual serine-proline rich (SPX) domain that was 
originally found in TN-Y [38].  
Comparison of human, mouse, and bovine TN-X sequences showed that the second 
XA repeat, the SPX region with ½ of an FN-III repeat, and the X2 repeat can be 
alternatively spliced.  
 
TN-Y contains a heptad repeat a small EGF-L region containing one complete and 2 
½ EGF-L repeats, an SPX-½FN-III domain, which is similar to that in TN-X and 12 
FN-III repeats [5].  
 
 
1.4. Tenascins - Isoforms, Domains and Function 
 
The diversity of TN-C isoforms represents an important mechanism to alter cell 
signalling and downstream functions by modulating binding interactions with different 
receptors or other components of the ECM.  
Alternative splicing of FN-III domains generates multiple TN-C isoforms. Those 
isoforms vary in number, in a species- and also in a cell type dependent manner [44]. 
In contrast, EGF-L repeats are expressed in the same way and do not alter in 
number in all isoforms.  
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Splicing of FN-III domains can be influenced by many factors including extracellular 
pH [45], TGF-β1 [46], and basic fibroblast growth factor (bFGF) [47, 48]. 
Fischer et al. demonstrated the function of different TN-C domains by deleting them 
from an intact chicken TN-C molecule (shown in Figure 4.) and scored for change in 
activity [49].  
 
 
 
 
Figure 4. Summary of functional characteristics of TN-C domains in recombinant 
molecules. Each variant is scored for promotion of cell adhesion by -, + or ++. Cell 
shape is indicated by  if the majority of the cells were round and by  if the 
majority of the attached cells were spread. Activities in inhibiting adhesion to 
fibronectin (Fn) or the promotion of neurite outgrowth at two time points, 8h or 24h 
after plating, are indicated by -, +, ++, or +++ (TN 190 = intact TN-C, EGF = 
epidermal growth factor like repeats, FN = FN-III repeats, FB = fibrinogen globe, FF = 
FN-III repeats and fibrinogen globe, EFN = EGF-L repeats and FN-III repeats) [49]. 
 
 
In single mutant molecules all EGF-L repeats, all FN-III repeats, or the FG were 
deleted. In double mutants the FN-III repeats were deleted together with either the 
EGF-L repeats or the FG, respectively. All TN-C variants were able to form correct 
hexameric molecules. In cell culture, intact TN-C and the mutant missing the FG did 
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not promote adhesion of chicken embryo fibroblasts. In contrast, molecules 
containing only the FG or the EGF-L repeats, were adhesive substrates and even 
supported cell spreading [49].  
 
Exceptionally, the fibrinogen globe holds a crucial function in promoting interaction of 
TN-C to cells. Without this initial binding step, the activities of all other TN-C domains 
are precluded. The EGF-L repeats have cell adhesion and neurite outgrowth 
stimulating function, which in the context of the FN-III repeats are counteracted [49].  
For this reason it is not surprisingly, that expression of larger TN-C variants, including 
FN-III repeats, has been correlated with increased cell migration [50], tissue 
remodelling [51], and invasiveness of carcinomas [52], whereas smaller molecules 
are expressed within more quiescent tissues and are associated with the production 
of a stable ECM.  
Numerous experiments have shown the connection between a specific domain and 
their function (Figure 4.) and respectively, a domain and the specific binding 
molecule or receptor [49]. Unfortunately, only a few domain interactions were 
described in detail (Figure 5.) [53]. 
The third FN-III type repeat contains a specific cell binding site, the RGD motive 
(amino acids: R = arginine, G = glycine, D = asparagine), to interact with the 
adhesion-promoting αvβ3 integrin (Figure 5.) [54]. The alternatively spliced A-D FN-
III domains (shown in red) bind the protein annexin II, and are considered in certain 
cell types to be counter adhesive, due to its ability to disrupt focal adhesions [55].  
In addition, the TN-C isoforms with excluded A-D FN-III domains differentially bind 
F11 contactin through the fifth and sixth FN-III domain. These TN-C molecules bind 
to fibronectin (FN) with higher affinity than the larger molecules, which include the A-
D domains. They are principal expressed in tissues characterised by the presence of 
an abundant ECM [56]. 
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Figure 5. Localisation of functional domains and interaction sides of mouse TN-C 
(TA domain = tenascin assembly domain, EGF-L repeats = epidermal growth factor 
like repeats, FN-III domains = fibronectin type III domains, FG = fibrinogen globe, 
RGD motive: R = arginine, G = glycine, D = asparagine) [53]. 
 
 
Perlecan, which supports the maintenance of the endothelial barrier and vascular 
homeostasis, binds to TN-C via its FN-III domains 3-5, whereas the alternatively 
spliced A-D domains of TN-C inhibit this interaction (Figure 5.) [5, 44]. 
In addition there may be a heparin binding site in the last FN-III domain of the 
alternative spliced region [55]. Other FN-III repeats as well as EGF-L repeats may 
mediate other cellular interactions including cell proliferation, neural cell adhesion, 
and immune modulation.  
 
In cell culture studies it was shown that TN-C specifically interacts with fibronectin. 
TN-C can bind to the FN-III 13 of the Hep-II site, thereby blocking cell binding to 
fibronectin through syndecan-4. This can cause enhanced proliferation of human 
glioblastoma and breast carcinoma cells that could be neutralised by the addition of 
recombinant FN-III 13 as well as by over-expression of syndecan-4 [57]. The FN-III 
domains 1-3 support binding, growth, and differentiation of postnatal day 6 (P6) 
cerebellar neurons in culture after 24 hours. Whereas the EGF-L domains and the 
alternatively spliced FN-III A1, A2, and A4 domains showed anti-adhesive properties 
on CNS neurons. Neurite outgrowth-promoting properties could be assigned to the 
alternatively spliced FN-III domains B, D, and domain 6. These findings suggest, that 
the developmental regulation of alternative splicing is functionally significant in CNS 
[58]. 
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Aortic smooth muscle cells (ASMC) expressed in response to injury an isoform 
containing only the FN-III domains A1 and A2. This isoform is up-regulated in aortic 
cells of newborn rats by stimulation of PDGF-BB, which is a potent chemo-attractant. 
In SMCs, derived from adult rat aorta, the expression of this isoform is markedly 
down-regulated [59].  
Under cell culture conditions the recombinant A1-A2 protein promoted SMC 
chemotaxis but not adhesion or proliferation, which suggests a new role of this 
specific TN-C isoform in the remodelling of vascular wall [59]. 
 
Several studies pointed out, that the human large TN-C isoform inhibited attachment 
of both human and rat ASMC to fibronectin [21].  
PDGF-BB induced TN-C biosynthesis resulting in generation of 3 different splice 
variants. The ability of PDGF-BB to up-regulate the expression of TN variants may 
cause destabilisation of interactions between cells and ECM and promote cellular 
migration [21].  
 
In mouse brain 27 different TN-C isoforms were identified [47]. The AD1 and AD2 
domains, which were present in human and chicken TN-C, were complete absent in 
mouse brain tissue. The A3 domain might be unique for primate TN-C. Whereas the 
human AD1 [60] and AD2 [61] domains were often in association with tumour 
formation. 
Tissue from P6 mice cerebellum compared with brain tissue without cerebellum 
showed a higher level of TN-C in brain tissue containing cerebellum. This 
observation stands in agreement with resent findings that the P6 cerebellum is the 
main source of TN-C mRNA in mouse brain, expressing different isoforms with 1 up 
to 6 alternatively spliced FN-III domains [47]. 
 
All FN-III domains have nearly same size (~270bp) [62] so it is necessary to analyse 
different isoforms with domain specific primer for PCR analysis and sequencing or 
antibodies in immunohistochemical (IHC) studies.  
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1.4.1. Tumour Development 
 
TN-C was originally discovered in 1983 as GMEM antigen [8]. In the meantime many 
studies suggested a supportive role for TN-C in tumour growth, metastasis, tumour 
angiogenesis, and inhibition of immune surveillance. Most reports described that TN-
C is involved in initiation of tumourigenesis and progression to metastasis. 
Furthermore, TN-C staining correlates often with tumour grade and strong 
immunohistochemical staining indicates in the majority of cases poor prognosis in 
tumour progression [22]. 
 
TN-C is highly expressed in tumour tissue in the majority of malignant solid tumours, 
including those arising in the brain, breast, uterus, ovaries, prostate, pancreas, colon, 
stomach, mouth, larynx, lung, liver, kidney, bladder, skin, bone, soft tissues, and in 
lymphomas [22, 63, 64].  
The two main and quantitative important variants arise by complete inclusion or skip 
of the whole alternatively spliced region including FN-III domains A1-A4, B, AD1, 
AD2, C, and D. Those two isoforms are known as TN-CS (small) and TN-CL (large) 
isoform. In contrast to physiologically adult tissues, where expression of TN-CL only 
rarely occurs, high expression levels can be detected in embryogenesis and during 
several processes of ECM remodelling including tumour progression [65].  
Designative therefore, the human AD2 domain was found in 1997 by Mighell et al. in 
oral cancer tissue [61] and the human AD1 domain was first observed in 1993 by 
Sriramarao et al. in a glioblastoma cell line [60].  
The mRNA expression patterns of the FN-III domains A1-A3 are very similar among 
the different carcinomas. Stronger alterations exist in the region from the domains B 
to D. In general, the domains AD1/C are rarely expressed. AD1 domain expression 
seems to be connected with compact invasion pattern [64].  
 
In 1999 it was shown the first time that expression of different TN-C domains is not 
only dependent on tumour type but also on tumour stage [66]. 
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1.4.2. Wound Healing 
 
Wound healing response starts immediately after tissue injury, whereas different cells 
(fibroblasts and platelets) and components, such as collagens, cytokines and growth 
factors (e.g. PDGF and TGF-ß) are crucial during this process. However, ECM 
proteins, such as fibronectin and TN-C are known to be important key players in 
wound healing [67]. 
In normal skin, TN-C is sparely expressed, predominantly in association with 
basement membranes. In contrast, TN-C expression increases in healing wounds at 
the wound edge in all skin layers, extending towards the normal skin. In particular, 
strong TN-C specific staining is expressed at the dermal-epidermal junction beneath 
migrating and proliferating epidermis [68]. TN-C is present throughout the ECM of 
granulation tissue, which filled full-thickness wounds, but TN-C is not detectable in 
the scar after wound contraction is complete. Interestingly, TN-C distribution pattern 
is spatial and temporal different from that of FN [68].  
 
In healing wounds dermal fibroblasts and epidermal keratinocytes are identified as 
origin of TN-C expression. Both cell types expressed the larger TN-C mRNA, but in 
contrast epidermal keratinocytes expressed additionally smaller transcripts at higher 
levels than dermal fibroblasts [69]. 
Within keratinocytes the presents of the 2 different transcripts can be up-regulated by 
inflammatory cytokines. Addition of IFN-γ slightly increased the level of large 
transcripts, whereas, TNF-α influences the expression of smaller TN-C transcripts. In 
contrast, IL-4 affected the expression of both, the large and small TN-C mRNAs [69].  
 
During corneal wound healing, human corneal epithelial cells (HCE) are the origin of 
2 fibronectins and TN-CL isoforms [70]. Distribution of fibronectin and TN-C showed a 
distinctly different pattern in HCE cells. Fibronectin showed clear fibrillar 
arrangement, whereas TN-C appears as diffuse patches underneath the cells [70].  
Also secretory mechanisms, comparing those two proteins, seem to bee quite 
different. Fibronectin is mainly present in the ECM and secreted into the culture 
medium, whereas TN-C is only present in the ECM [70]. 
Adhesion experiments showed that HCE adhere to fibronectin through distinct 
integrins in a process that can be modulated by TN-C [70]. 
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In normal skeletal muscle TN-C is not present, but in cell culture studies Gullberg et 
al. found out that fetal muscle cells synthesise TN-C [19]. Considering this findings 
muscle TN-C expression was analysed, because it has been reported that TN-C is 
up-regulated in endomysial ECM after denervation and following trauma.  
TN-C immunoreactivity was examined in muscle samples from patients with 
Duchenne/Becker muscular dystrophy (DMD/BMD) and myositis, both of which were 
characterised by muscle degeneration and various degrees of muscle regeneration. 
TN-C expression was markly up-regulated in DMD/BMD and in myositis, and in both 
diseases this correlates to macrophage invasion and T-cell accumulation [19]. 
 
 
1.5. Myocardial Infarction 
 
Myocardial infarction or acute myocardial infarction (AMI) is defined as death or 
necrosis of myocardial cells (Figure 6.). It occurs when blood supply to the 
myocardial tissue is interrupted. The resulting myocardial ischemia is most commonly 
due to occlusion of a coronary artery following rupture of an atherosclerotic plaque. 
The resulting ischemic period if left untreated, can cause damage and/or death of the 
affected myocardium [71]. 
Myocardial infarction is the leading cause of death for both sexes all over the world. 
The median age of first acute MI is higher in women than men (65 versus 56 years). 
Apart from previous cardiovascular disease and familiar history of coronary heart 
diseases at young age, there are nine modifiable risk factors, standing in association 
with MI in women and men. Those factors include: hypertension/high blood pressure, 
diabetes mellitus, lack of exercise, excessive alcohol consumption, high blood levels 
of cholesterol: low and high density lipoprotein (LDL and HDL), tobacco smoking, 
ascendance, high risk diet, and chronic high stress levels [72]. 
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Figure 6. Schematic diagram of the infarcted versus the healthy heart. (A) The left 
ventricle has a thick muscular wall (shown in cross-section). (B) After infarction 
cardiomyocytes in the left ventricle are deprived of oxygen and die. (C) This 
undersupply of oxygen eventually cause left ventricular dilatation and wall thinning 
[73]. 
 
 
1.5.1. Cardiac Remodelling and Repair Mechanisms Post Infarction 
 
The ECM in healing myocardial tissue undergoes dynamic changes that dramatically 
alter cell microenvironment. ECM is not only a stiff network, and the composition of 
the ECM plays a crucial role in regulating cellular behaviour, cell interactions through 
specific surface receptors, cell phenotype, and gene expression. So the ECM can 
resist altering mechanical properties of the left ventricle [30]. 
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Post infarction myocardial structure, function and geometry are dramatically affected 
and cardiac repair mechanisms are immediately activated (Figure 7.). 
Those mechanisms are regulated through a dynamic and precise timed dependent 
activation and/or repression of inflammatory pathways, followed by alteration to 
granulous and fibrous tissue deposition and finally the formation of a solid scar [74]. 
Necrosis of cardiomyocytes triggers production of pro-inflammatory cytokines and 
chemokine, which leads to recruitment of inflammatory cells (neutrophils, 
macrophages and monocytes) into the infarcted area. This repair mechanism is 
important for the formation of a stabilised scar, increasing the tensile strength of the 
wound [74]. Production of growth factors leads to fibroblast migration, proliferation 
and activation. Activated fibroblasts and myofibroblasts produce most of the ECM 
macromolecules [30]. Collagen production is up-regulated and an extensive 
microvascular 3D-organised network is formed. Furthermore, the renin-angiotensin-
aldosterone system (RAAS) is affected, which is a hormone system regulating blood 
pressure and water balance [30]. 
Additionally, a fine balance between activated MMPs that degrade ECM components 
and TIMPs that inhibit MMPs action, is necessary for regulated and `normal´ 
remodelling and inhibit excessive matrix degeneration [30]. 
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Figure 7. Temporal changes during the healing process after myocardial infarction. 
Schematic showing pathways leading to formation of the infarct scar (R = receptor, 
RAAS = renin-angiotensin-aldosterone system, ECCM = extracellular collagen 
matrix, AT1/2R = angiotensin II type 1/2 receptor) [30]. 
 
 
1.5.2. Biomarkers - Laboratory Diagnosis of Myocardial Infarction 
 
Serum/blood biomarkers have become the `gold standard´ for MI diagnosis. Morrow 
and de Lemos have set out three criteria a biomarker should fulfil to be useful 
clinically [75]: (1) Can the clinician measure it? (2) Does it add new information? (3) 
Does it help the clinician to manage patients?  
But an ideal biomarker of myocardial injury should possess more than that 
characteristics (Figure 8.). 
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Figure 8. Summary of the ideal characteristics of biomarkers [76]. 
 
 
Actually none of the available tests for myocardial biomarkers meets all this criteria. 
No common biomarker is completely sensitive and specific for MI, especially in the 
acute phase within about 6h following the onset of chest pain. In this timeframe most 
emergency physicians have to make diagnostic and therapeutic decisions [77]. 
Timing and the correlation with patient symptoms, electrocardiograms and 
angiographic studies are very important [78]. 
Therefore, a multi-marker strategy has been reported to be useful in refining risk 
stratification among patients with acute coronary syndromes, and there is growing 
interest in this approach for categorising heart failure [79]. 
The following tests are available as markers for acute myocardial infarction: 
 
Cardiac troponins, troponin I and T, are the current `gold standard´ for the detection 
of myocardial necrosis [80]. After MI troponin levels increase within 2 to 4h and 
persist for days in the blood (Figure 9.). Troponin I will remain elevated up to 5 to 10 
days and troponin T up to 2 weeks [78].  
 
Before the appearance of troponin assays, creatine kinase (CK) and its CK-MB 
fraction, which is specific for cardiac muscle were the `gold standards´ for diagnosing 
of MI. Increases in plasma levels usually occur 6-12h post MI, peaking at 24h, and 
returning to baseline after 36-72h (Figure 9.) [81]. 
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Figure 9. Time course of various biomarkers in the blood after acute myocardial 
infarction (AMI). Shown are the time concentrations/activity curves for myoglobin, 
creatine kinase (CK) isoforms, troponin and CK-MB after large and small infarctions 
(CV = coefficient of variation) [78]. 
 
 
Whereas troponins have become the most sensitive test to detect myocardial 
necrosis, B-type natriuretic peptide (BNP) and the amino terminal fragment of 
proBNP called NT-proBNP are increasingly recognised as the most sensitive test to 
detect cardiac stress and heart failure [80]. 
 
Additionally, myoglobin [81], lactate dehydrogenase (LDH) [82], C-reactive protein 
(CRP) [78], and serum glutamate oxaloacetate transaminase (SGOT) [76] can be 
useful to detect myocardial injury.  
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1.6. Tenascin-C in the Heart  
 
 
1.6.1. Tenascin-C in Early Heart Development  
 
TN-C is expressed during wound healing and remodelling processes in various 
tissues. Within the heart, TN-C is expressed only at the very early stage of 
organogenesis during embryonic development. In healthy adult myocardium only the 
chorda tendinae of papillary muscles is TN-C positive [83]. The remaining healthy 
heart is TN-C negative, but TN-C reappears in the myocardium under various 
pathological conditions, such as dilated cardiomyopathy, myocarditis, and myocardial 
infarction [84, 85].  
 
In heart organogenesis, mesenchymal-epithelial transformation of the precardial 
mesoderm is an important step leading to differentiation of cardiomyocytes. A 
population of mesodermal cells elongate and differentiate to cardiomyocytes. This 
process requires extensive alteration of cell shape, arrangement of cells, and cell-cell 
interactions, which transmit important signals for differentiation of cardiomyocytes 
[86, 87]. 
TN-C is expressed in the epithelialising mesoderm, suggesting that the molecule 
could be involved in this dynamic cell activity.  
Once cardiomyocytes become differentiated, they stop TN-C expression, with the 
exception of cells in the out-flow tract of the heart. It seems that cells of the out-flow 
tract are a special subpopulation of cardiomyocytes [88]. 
 
Imanaka-Yoshida et al. analysed TN-C and TN-X expression patterns in early cardiac 
development within wild-type and TN-C knockout mice [88]. This study demonstrated 
that TN-C is expressed at distinct time points and sites during early heart 
development in mice starting at E7.5. In contrast, TN-X is initially expressed at E11 
as scattered small spots along the inter-ventricular groove, the AV groove, and over 
the surface of the atrium. 
TN-C was transiently expressed by differentiating pre-cardiac mesodermal cells, 
cardiomyocytes in the looping out-flow tract, endocardial cells forming cushion 
tissues, and mesenchymal cells in the pro-epicardial organ (PEO), which are the 
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precursors of coronary vessels. 
Despite restricted expression during cardiogenesis, the hearts of TN-C null mice 
developed normally [88]. 
The speculation that TN-X may compensate for the loss of TN-C cannot be 
approved. No difference in TN-X expression can be observed in TN-C null mice 
compared to wild-type mice and no TN-X was detected at sites where TN-C must be 
essentially expressed [88]. 
  
 
1.6.2. Tenascin-C in Myocardial Remodelling 
 
Myocardial tissue remodelling plays an important role in progressing heart failure. In 
the healthy myocardium, myocytes are embedded in the ECM meshwork and a 
balance between MMP and TIMPs exist. An imbalance with increased MMP up-
regulation is associated with ventricular dilatation and remodelling. Ventricular 
function can also be impaired by an abnormal increase in collagen synthesis, 
resulting in excessive fibrosis [79].  
 
 
1.6.2.1. Tenascin-C in Post Myocardial Infarction Remodelling 
 
The presence of TN-C and fibronectin in human myocardial tissue at different time 
points post MI (6h to 17 years) were analysed [67]. In the control group of healthy 
myocardium, fibronectin immunostaining was found in the subendothelial space in 
vessels. TN-C was completely absent in normal myocardium. While fibronectin was 
demonstrated in ischemic cardiomyocytes within 1 day, TN-C was found 4-6 days 
post infarction and was located at the margin of the area of infarction.  
TN-C expression then shifted from the margin to the centre of infarction, where it 
could be found 2-3 weeks. More than 4 weeks after infarction, the scar tissue 
consisted of collagen fibres with sparse fibroblasts. By that time, both TN-C and 
fibronectin expression had disappeared.  
Another interesting observation was the presence of TN-C, but not fibronectin, 
surrounding vacuolated glycogen-rich cells, or so-called hibernating cardiomyocytes 
[67]. 
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In a rat model it was shown that within 24h after permanent coronary ligation, 
interstitial fibroblasts in the border zone between infarcted and non-infarcted 
myocardium, where extensive remodelling occurred, started to express TN-C mRNA 
[85]. TN-C loosens cardiomyocyte-matrix adhesion, which could help cell 
rearrangement. TN-C expression was down regulated on day 7 and was no longer 
apparent 14 days post MI. Three days post MI necrotic myocardial tissue began to be 
replaced by granulation tissue. Cardiomyocytes did not express TN-C, only 
fibroblasts at developing fronts and around necrotic cardiomyocytes were positive for 
TN-C. 
These results suggest that TN-C, which is up-regulated during acute/early phase 
after MI in interstitial cells, has an important role in loosening strong adhesion to 
connective tissue and helping in the rearrangement of surviving cardiomyocytes.  
The mechanisms how TN-C, which is generally thought to be a counter-adhesion 
molecule, can affect cell adhesion are quite complex. 
In healthy myocardial tissue cardiomyocytes are firmly anchored to connective tissue 
with costamere complexes containing integrin, talin, vinculin, and laminin [85]. TN-C 
inhibits cardiomyocytes from forming those costameric contacts but increases the 
number of cells with non-costameric attachment [85]. 
 
TN-C may have a dual role in cardiac healing after MI. TN-C may loosen 
cardiomyocytes from the ECM, causing slippage of cardiomyocytes (Figure 10.). 
Deadhesion of cells through loss of actin fibers and focal adhesion plaques support 
cell migration and cell invasion of inflammatory cells post infarction [3].  
In addition, TN-C up-regulates MMPs [89], promoting degradation and 
rearrangement of the ECM and loosen tissue, which leads to an increasing risk of 
wall thinning, cardiac dilatation, and rupture [90].  
TN-C may also increase production of matrix components to strengthening the 
cardiac matrix. Increased production of ECM molecules, in contrast, may occur by 
TN-C mediated recruitment of myofibroblasts [85], which are the main cells involved 
in production of new collagen shortly after MI.  
The elastic properties of TN-C, due to the stretch-induced unfolding of its FN-III 
domains, may also help to resist the increased mechanical loading to which the 
border zone of the infarct is subjected [42].  
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Figure 10. A schematic diagram showing the possible role of matricellular proteins, 
including TN-C, during left ventricular remodelling of the heart [3]. 
 
 
Whether TN-C reappearance after cardiac injury is beneficial or detrimental remains 
unclear, considering the paradoxical functions of TN-C in ECM remodelling. The 
precise role of TN-C in matrix remodelling after cardiac injury or stress requires 
further investigation in mice lacking the TN-C gene [3].  
It was hypothesised that TN-C expression levels might be useful for the diagnosis 
and determination of left ventricular (LV) remodelling following myocardial infarction. 
Serum TN-C levels in patients with AMI and old myocardial infarction (OMI) were 
examined [91]. In the AMI group TN-C was significantly increased and peaked at day 
5, then gradually decreased, although remained elevated at day 28. 
TN-C levels were significantly higher in the LV remodelling group than in the non-
remodelling group. AMI patients with high TN-C levels were at much higher risk of 
major adverse cardiac events (MACE) for up to 5.5 years [91]. 
Thus, serum TN-C levels in acute stages following infarction might be a predictive 
biomarker of LV remodelling during the recovery phase and prognosis.  
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In a myocardial wound healing model TN-C knockout mice were compared to wild-
type mice after electrical injury to the myocardium [92, 93]. In knockout mice, 
myocardial repair seemed to proceed normally, but the appearance of myofibroblasts 
was delayed. These results indicate that TN-C is an important key player by 
stimulating cell migration and differentiation and promote recruitment of 
myofibroblasts in the early phase of myocardial repair [92]. 
 
 
1.6.2.2. Tenascin-C in the Heart Failing Process 
 
In biopsy specimens from patients with acute myocarditis the degree of TN-C 
expression correlates with the severity of histological lesions - maybe TN-C reflects 
disease activity in cases of human myocarditis [94].  
Furthermore, TN-C expression correlates with cardiac injury and inflammation, and 
the TN-C expression level has been proposed as a marker for the severity of viral 
myocarditis [84]. 
 
Imanaka-Yoshida et al. analysed TN-C expression in a myosin-induced autoimmune 
myocarditis mouse model [84]. TN-C expression was up-regulated at a very early 
stage of myocarditis (at day 14-16). During the active phase of myocarditis (about 
day 45), two isoforms of TN-C at 210kD and 250kD were identified in mouse 
myocardium, while only a faint band of the smaller isoform with 210kD was detected 
in the normal myocardium. TN-C immunostaining was always observed at the 
periphery of necrotic or degenerating cardiomyocytes in foci of inflammation. The 
expression level correlated with histological evidence of inflammatory activity [84]. 
 
Especially fibroblasts have a crucial role in regulating ECM remodelling, 
Frangogiannis et al. analysed the phenotypic characteristics of interstitial fibroblasts 
[95]. Expression of smooth muscle myosin heavy chain and TN-C was analysed, in 
the interstitium of hibernating human myocardium to examine the relation to recovery 
of myocardial function after revascularisation [95]. 
They demonstrated persistent interstitial deposition of TN-C in the dysfunctional 
human myocardium, which suggests an active process of ECM remodelling. The TN-
C:collagen ratio, a marker of TN deposition in the cardiac interstitium, was 
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significantly higher in segments with recovery, suggesting the presence of an active 
remodelling process in hibernating segments. These findings support the concept 
that ischemic cardiomyopathy represents a dynamic process associated with 
continuous deposition of ECM. Resulting to a state of extensive fibrosis potentially 
associated with a lower chance of functional recovery [95].  
 
Sato et al. analysed TN-C up-regulation in chordae tendineae of the anterior cusp of 
the left ventricular papillary muscle with aging [83]. TN-C distribution was studied in 
both, a 20s age group and an 80s-90s age group. Interestingly, concentrations of TN-
C increased in response to mechanical stress and aging.  
 
TN-C level was analysed by immunochemistry in biopsy specimens of hearts 
obtained from patients with idiopathic dilated cardiomyopathy (IDC) [96]. IDC is a 
disorder of unknown aetiology characterised by left ventricular cavity enlargement 
and wall thinning, in association with reduced left ventricular wall motion. In IDC 
specimens TN-C was distributed in the enlarged perimysium and endomysium near 
replacement fibrotic lesions close to necrotising myocytes and in the peripheral 
portion of the replacement fibrotic lesions. Concluding that TN-C plays an important 
role in the initiation of replacement fibrosis in patients with IDC.  
Furthermore, circulating serum TN-C level was analysed in a small population of 31 
cases in patients with IDC and demonstrated that serum TN-C is up-regulated after 
IDC [97]. Also a positive correlation between circulating TN-C and BNP levels, which 
is an indicator for cardiac insufficiency, had been demonstrated. Patients with 
detectable cardiac troponin T, a marker of ongoing myocardial damage in chronic 
heart failure, had higher TN-C levels than those without it. Circulating levels of TN-C 
were positively correlated with those of pro-collagen type III amino-terminal peptide, 
a marker of cardiac fibrosis synthesis in myocardial infarction and chronic heart 
failure. Suggesting, that increased levels of circulating TN-C indicate ongoing 
replacement fibrosis after a loss of cardiomyocytes in IDC [97]. 
These results confirm the histopathologic observations of Tamura et al. [96], who 
showed that TN-C is specifically localised along the margin of fibrotic areas. 
Terasaki et al. confirmed preliminary results obtained from this small study population 
with a larger dilated cardiomyopathy (DCM) population (n = 107) and showed a 
clearer association between higher TN-C levels and LV remodelling, as well as LV 
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dysfunction. Serum TN-C levels were analysed by enzyme-linked immunosorbent 
assays (ELISA) and demonstrated that increased serum TN-C levels indicate the 
severity of heart failure, left ventricular dysfunction and remodelling in patients with 
DCM [98]. 
 
  
1.7. Medical Applications of Tenascin-C 
 
Besides the extensive use of TN-C antibodies in immunohistochemistry, the use of 
TN-C antibodies has been also expanded to in vivo studies. In the case of TN-C, 
antibodies have been used for oncological diagnosis and therapies [35]. It was found 
that TN-C expression is correlated with angiogenesis and local infiltration of normal 
tissue by tumour cells of various types of carcinomas [99].  
Even targeting human antibodies specific to alternatively spliced domains of the large 
TN-C isoform are promising building blocks for the development of antibody-based 
pharmaceuticals [100].  
In a phase-II trial 131I-labeled monoclonal antibodies to human TN-C have yielded 
promising results when used as radio-immunotherapy for patients with newly 
diagnosed malignant gliomas [101]. These treatments have been pioneered in 
patients with brain tumours [102, 103]. Since TN-C is weakly expressed in normal 
adult brain, but strongly expressed in those tumours, this radiolabeled tool allows 
selective destruction of tumour cells. The antibody anchors the radioisotope direct at 
the tumour tissue side, which is rich in TN-C and thus provide for local radiation.   
Yet another promising development is the isolation of size-minimised and nuclease-
stabilised TN-C aptamers, which can be considered as oligonucleotide analogous of 
antibodies. Aptamers exhibit high affinity and specificity for their cognate proteins. 
They may be beneficial for tumour targeting due their smaller size than antibodies, 
and could be used for targeted delivery of radioisotopes [104].  
 
A number of studies have investigated TN-C levels in body fluids, such as synovial 
fluid of patients with rheumatoid arthritis in order to assess the possibility of using 
TN-C as a marker of specific diseases [105]. Increased serum TN-C levels are in 
conjunction with neoplasia and inflammation, including inflammatory bowel disease 
(IBD) [106] and chronic hepatitis C (CHC) [107]. Elevated TN-C serum levels were 
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observed, as mentioned before, in pathologies such as myocardial infarction [91] and 
IDC [97]. TN-C levels in patients with dilated cardiomyopathy showed a significantly 
positive correlation with NYHA (New York Heart Association) functional class [98]. 
Furthermore in patients with IDC, levels were negatively correlated with the left 
ventricular ejection fraction, positively correlated with left ventricular end-systolic 
diameter and BNP level. Additionally, levels of circulating TN-C were higher in 
patients with detectable cardiac troponin T than in those without [97]. 
 
Another, indirect way of therapeutic strategy may be the determined regulation of 
MMPs, which play an important role in degrading TN-C. Regulation of myocardial 
MMP expression and activity may be important for controlling myocardial matrix 
remodelling in the developing of heart failure [108]. 
Mouse models have been created with mutations in the MMP/TIMP genotype and will 
likely act as a major tool for further analyses [108]. Determination between different 
TN-C isoforms, knowledge of shift in isoform expression and potential interaction 
partner will be subject of further studies to understand the complex function of this 
protein. 
Nevertheless, the broad distribution of tissues capable of synthesising TN-C, and its 
induction under so many pathological conditions, suggest that TN-C presence in 
serum is not sufficiently specific to be useful in diagnosis. But measurement of TN-C 
levels may, however, be useful in assessing prognosis and response to treatment 
[91, 98, 106, 107]. 
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Aim of the thesis 
 
In contrast to small TN-C isoforms, which are up-regulated in healthy ECM, large TN-
C isoforms are up-regulated under pathologic conditions [44]. 
Whereas the healthy, adult heart is TN-C negative, TN-C protein is detectable in 
injured cardiac tissue after myocardial infarction (MI) [85]. 
This protein up-regulation and shift in isoform expression in the myocardial healing 
process demonstrates a potent mechanism to influence cell-cell and cell-ECM 
interactions [44]. 
  
The aim of this thesis was to show a detailed time-dependent expression pattern of 
the matricellular protein TN-C in the early remodelling process post MI (12 hours to 
14 days). Furthermore, the complete rat TN-C cDNA sequence was analysed and the 
up-regulation of four specific TN-C isoforms in left ventricular remodelling after 
myocardial infarction were demonstrated.  
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2. MATERIAL AND METHODS 
 
 
2.1. Animal Model of Myocardial Infarction 
 
Male Sprague-Dawley rats (Core Unit for Biomedical Research, MUW, Himberg, 
Austria) weighting 300 ± 50g were used in the study.  
All animals had free access to standard rat chow and fluid during the observation 
period and received human care in compliance with the European Convention on 
Animal Care and the local animal research advisory board. 
 
Myocardial infarction was induced by ligation of the left anterior descending coronary 
artery (LAD) according to the technique of Pfeffer et al. [109] as described recently 
[110, 111]: initially, rats were anaesthetised intraperitoneally with a mixture of 
xylazine (1mg/100g bodyweight, i.p.; Rompun®, Bayer Health Care, Vienna, Austria) 
and ketamine (10mg/100g bodyweight, i.p.; Ketasol®, Graeub Veterinary Products, 
Senden-Bösensell, Germany). Rats were shaved on their left side between the axilla 
and the costal arch and placed on the operation table. Rats were intubated with a 
fine polyethylene tube and ventilated mechanically by a rodent ventilator using 
oxygen and room air (60 min-1). 0.2% isofluran (Forane®, Abbott, Kent, United 
Kingdom) was added to the oxygen-air mixture.  
Subsequently, the skin was incised over the 4th intercostal space. The underlying 
musculature was blunt dissected in order to reveal the intercostal musculature. The 
chest was entered via left thoracotomy in the fourth intercostal space, and a pair of 
retractors was used to open up the cavity. 
After removing the pericardium, the beating heart and the LAD was visualised and a 
6-0 prolene* ligature (Ethicon, Edinburgh, United Kingdom) was placed around the 
LAD (Figure 11.) beneath the left auricle.  
After coronary ligation and 1h post surgery lidocaine (1mg/100g bodyweight, i.m.; 
Xylanaest purum 2%, Gebro Pharma, Fieberbrunn, Austria) was applied. 
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Figure 11. Model of ligation [112]. 
 
 
Immediately after confirming the efficacy of the ligation (wanly coloration of the 
anterior wall of the ventricle) the chest was closed after being evacuated by a small 
polyethylene cannula and isofluran supply was stopped.  
Sham operated rats underwent the same procedure, except the ligature around the 
LAD.  
After myocardial infarction the perioperative mortality in the first 48h was about 25%. 
During the follow-up period no animal died. 
The skin was sutured with a 3.0 vicryl* plus suture (Ethicon, Edinburgh, United 
Kingdom). Immediately after awakening, the rats were placed back into their cage. 
Three hours after surgery a subcutaneous analgetic injection of Piritramid 
(0.01ml/100g bodyweight; Dipidolor®, Janssen-Cilag Pharma, Vienna, Austria) was 
applied.  
 
For studying TN-C expression levels eight different time points post MI were 
selected: 0.5, 1, 2, 3, 5, 7, 10, 14 days post MI, and compared to a sham operated 
control group (Table 1.). In this study only animals with a myocardial infarction of ≥ 
20% of the left ventricle were included. 
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Days post MI Group size (total) Group size (MI ≥  20%) 
0.5 16 4 
1 16 6 
2 16 7 
3 16 7 
5 16 6 
7 16 5 
10 16 5 
14 16 6 
Sham control 10 10 
Reserve 40 - 
Total 178 56 
 
Table 1. Study design (MI = myocardial infarction). 
 
 
2.2. Sample Preparation  
 
After 0.5 to 14 days of survival the rats were sacrificed. Hearts were excised quickly 
and put into ice-cold saline. To analyse free wall and scar tissue within cross sections 
hearts were cut mid-papillary (Figure 12.). The upper part was used for histological 
analysis and fixed in 7.5% paraformaldehyde (SAV Liquid Production, Flintsbach, 
Germany) at 4°C. After fixation tissue samples were embedded in paraffin (Paraplast 
Plus*; McCormick Scientific, St. Louis, USA) and cut into 5µm slices. 
In contrast, the lower, apical part of the heart was used for isolation of RNA and 
proteins. Therefore, samples were collected from scar tissue and the non-infracted 
free wall area of the LV. Specimens were shock-frozen using liquid nitrogen 
immediately after harvesting and stored at -80°C. 
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Figure 12. Schematic diagram of sample preparation. Hearts were cut mid-papillary 
(indicated by the dotted line; LAD = left anterior descending coronary artery) [113]. 
 
 
2.3. RNA Isolation 
 
For RNA isolation 1ml TRI-reagent (Sigma, Steinheim, Germany) was used to 
homogenise 50-100mg cardiac tissue. Samples were incubated 5min at RT before 
0.1ml BCP/ml TRI-reagent was added (1-bromo-3-chloro-propane; Sigma, 
Steinheim, Germany). Samples were mixed well, incubated 2-15min at RT and 
centrifuged for 15min at 4°C at 12.000xg. 
Following centrifugation, the mixture was separated into a lower red phenol-
chloroform phase, an interphase, and a colourless upper aqueous phase. RNA 
remains exclusively within the aqueous phase.  
The aqueous phase was transferred to a fresh tube, and the organic phase was 
saved for protein isolation. From the aqueous phase RNA was precipitated. 
Samples were mixed with 0.5ml isopropyl alcohol/ml of TRI-reagent (Sigma, 
Steinheim, Germany), incubated 5-10min at RT and centrifuged at 12.000xg for 8min 
at 4°C. RNA precipitate was visible as a small white pellet on the side and bottom of 
the tube. Supernatant was removed and the RNA pellet was washed two times with 
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75% ethanol (Merck, Darmstadt, Germany) and centrifuged at 7.500xg for 5min at 
4°C.  
Finally the RNA pellet was briefly air-dried and dissolved in RNase-free H2O. RNA 
was quantified by spectrophotometric measurement of the absorbance at 260/280nm 
and RNA samples were stored at -80°C until further processing. 
 
 
2.4. Protein Isolation 
 
Proteins were precipitated from the phenol-ethanol supernatant (approximate 
0.8ml/ml of TRI-reagent). Furthermore 1.5ml isopropyl alcohol/ml of TRI-reagent was 
added for initial homogenisation. Samples were incubated for 10min at RT and 
protein precipitates were sedimented at 12.000xg for 10min at 4°C. Supernatant was 
removed and the protein pellet was washed 3 times in 1.8ml wash solution containing 
0.3M guanidine hydrochloride (Sigma, Steinheim, Germany) dissolved in 95% 
ethanol. During each wash cycle, the protein pellet was stored in the wash solution 
for 20min at RT and centrifuged at 7.500xg for 5min at 4°C. After the third wash step 
protein the pellet was washed 2 times in ethanol and centrifuged at 7.500xg for 5min 
at 4°C. Supernatant was removed and protein pellet was air-dried for 5-10min. Pellet 
was dissolved in 1% sodium dodecyl sulfate (SDS; Sigma, Vienna, Austria) by 
pipetting up and down. 
Bradford protein assay (Bio-Rad Laboratories, Munich, Germany) was used to 
measure spectrometrical the protein concentration of all samples according to the 
manufacturer’s instructions,  
Samples were stored at -20°C for future use.  
 
 
2.5. cDNA Synthesis 
 
For cDNA synthesis 2.5µg sample were used with either 0.5µg oligo (dT)18 or specific 
TN-C primer (Tnc-3_rev, Tnc-8_rev, Tnc-14_rev, and Tnc-18_rev; see Table 3.; 
VBC, Vienna, Austria). All primers were designed according to mouse (GenBank, 
NM_011607) and human (GenBank, NM_002160.1) mRNA TN-C sequence. To 
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reach the total volume of 14µl, ddH2O was added. Samples were incubated at 70°C 
for 5min and chilled on ice. After adding of 4µl 5x reaction buffer (250mM Tris-HCl, 
pH 8.3 at 25°C, 250mM KCl, 20mM MgCl, 50mM DTT) and dNTP mix (500µM/dNTP) 
samples were incubated at 42°C for 5min (Fermentas, Vilnius, Lithuania).  
For the first strand synthesis 1µl Superscript II Enzyme (Affymetrix, High Wycombe, 
United Kingdom) was added and incubated for 1h at 42°C. Reaction was terminated 
at 70°C for 10min followed by cooling down on ice. 
 
2.6. PCR 
 
To get a total volume of 25µl, 2µl sample, 2.5µl primermix with forward and reverse 
primer (25µM/primer; VBC, Vienna, Austria), 0.5µl dNTPs (10mM), 1µl dimethyl 
sulfoxide (DMSO), 2.5µl 10x buffer+MgCl2 and 0.2µl long PCR enzyme mix (5u/μl) 
were mixed (Fermentas, Vilnius, Lithuania). 
In Table 2. TN-C and GAPDH PCR protocols are summarised and in Table 3. all 
PCR and sequencing primers, designed by using Primer 3 Software (http: 
//frodo.wi.mit.edu/), were listed. 
 
 
 TN-C  GAPDH 
Step Temperature Time Cycles  Temperature Time Cycles 
1. 95°C Pause   94°C 5min  
2. 96°C 5min   94°C 1min  
3. 95°C 40sec   56°C 1min  
4. 60°C 1min   72°C 1min x39 
5. 72°C 3min x39  72°C 10min  
6. 72°C 5min   15°C Pause  
7. 15°C Pause      
 
Table 2. Protocols for TN-C and control GAPDH PCR.
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Primer Sequence (5´-3´) Length (bp) 
Tnc-1_for GCCAGCCATTGCCACTGT 18 
Tnc-2_for AAAATGCAGCCACAGTCAGC 20 
Tnc-3_rev GCCCATCAAATGCCCAAG 18 
Tnc-4_rev CGCCTGCCTTCAAGATTTC 19 
Tnc-5_rev CGCCTGCCTTCCAGATTTC 19 
Tnc-6_rev CGCCTGCCTTCMAGATTTC 19 
Tnc-7_for ACAGTGGATGGGGAAAACCA 20 
Tnc-8_rev AATCCCTTCATGGCAATCACACT 23 
Tnc-9_for CGAAGGTGGGGTCCTCAAGA 20 
Tnc-10_for AGGTGAAAGATGTCACAGACACCA 24 
Tnc-11_for CAAGCCACAACCAAAACCACA 21 
Tnc-12_rev TGCTTTTTGGTATCTCTGATCCTG 24 
Tnc-13_for TGTAATCTCAGAGGCCAGTGC 21 
Tnc-14_rev GTGTGGGGCTCAGGTCTTTC 20 
Tnc-15_for GCTCAGTGGATCTAGAGTCAACGA 24 
Tnc-16_rev TCGTTGACTCTAGATCCACTGAGC 24 
Tnc-17_for  ACCGGAGAAGACTGTAGCCAAC 22 
Tnc-18_rev AGTCTGGGTCATGTCAGCCTCTA 23 
Tnc-19_for ATGAGATGCGGGTCACTGAGTA 22 
Tnc-20_rev GTAAGTCCCTGGGTGCATCAAT 22 
Tnc-21_for TTCTTYCAAGAAGATYRGGGACA 23 
Tnc-22_for GTACCCTASAGMYCTAGAG 20 
Tnc-23_for GAGCCAGGGCAAGAATACAC 20 
Tnc-24_rev GTAATAGCGGGTGGCTGCT 19 
Tnc-25_for AGAGACACCTAGCCAATCCAA 21 
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Tnc-26_rev GTTTTCTCTGGGCCCCATT 19 
Tnc_for_m+r GCATCCGTACCAAAACCATCAGTA 24 
Tnc_rev_m+h+r CAGTGGCCTCTCTGAGACCTGTTA 24 
GAPDH_for CCATCACCATCTTCCAGGAGC 21 
GAPDH_rev GGCAGTGATGGCATGGACTG 20 
 
Table 3. Summary of TN-C and GAPDH primer used for PCR analysis and 
sequencing. 
 
 
2.7. Sequencing 
 
All sequences were obtained from purified or pure PCR products (4base Lab, 
Reutlingen, Germany). To purify PCR samples, probes were run on a 1% agarose 
gel (UltraPureTM Agarose; Invitrogen, Carlsbad, USA). Gel bands were cut out of the 
gel and purified by using GFXTM PCR DNA and gel band purification kit (GE 
Healthcare, Freiburg, Germany). Samples were analysed, and different isoforms 
were identified by using Codon Code Aligner Software (Version 2.0.2.; CodonCode 
Corporation, Dedham, USA). 
 
 
2.8. Real Time-PCR 
 
Real-time PCR was performed by using LightCycler-RNA Master SYBR Green I for 
GAPDH protein and Universal Probe Library for TN-C (Table 4.), according to the 
manufacturer’s instructions (Roche Applied Science, Mannheim, Germany). Primers 
(Table 5.) were designed using Primer 3 Software (http: //frodo.wi.mit.edu/). 
Amplification conditions included an initial incubation at 61°C for 20min, followed by 
incubation at 95°C for 30sec and 50 cycles of 95°C for 1sec. The respective 
annealing temperature was 63°C for TN-C and 65°C for GAPDH for 10sec and 72°C 
for 10sec, followed by a melting step from 45°C to 95°C, increasing 0.1°C/sec and a 
final cooling to 40°C. Finally data were analysed by using LightCycler Software 
 Material and Methods  
 
 
 55 
(Version 3.5; Roche Applied Science, Mannheim, Germany). 
Primer efficiency was 1.90 for TN-C and 1.85 for GAPDH primer. 
 
 
TN-C GAPDH 
H2O 10µl H2O (Nr. 3) 7.2µl 
UPL Probe #71 (1:5) 1µl White Cap (Nr. 2) 1.3µl 
Primer rev (25pmol/µl) 1µl Primer rev (10pmol/µl) 1µl 
Primer for (25pmol/µl) 1µl Primer for (10pmol/µl) 1µl 
Red Cap 1 4µl Red Cap 7.5µl 
Probe 3µl Probe 2µl 
Total 20µl  Total 20µl 
 
Table 4. Diagram of TN-C and GAPDH real time-PCR mix. 
 
 
Primer Sequence (5´-3´) 
Length 
(bp) 
Fragment size  
(bp) 
Tnc_for AGGGTTTCACTGGGGAAGA 19 
Tnc_rev CCTGGTCATTGCAGTCATTG 20 60 
GAPDH_for ACAGTCCATGCCATCACTGCC 21 
GAPDH_rev GCCTGCTTCACCACCTTCTTG 21 265 
 
Table 5. Summary of TN-C and GAPDH primer used for real time-PCR analysis. 
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2.9. Histological and Immunohistochemical Analysis 
 
 
2.9.1. H&E Staining and Infarct Size Measurement 
 
Before staining, slices were deparaffinised in xylene and dehydrated through a 
graded ethanol series (100%, 96%, 2x80% and 2x70% EtOH). 
H&E stained slices (Mayers Haematoxylin; Sigma, Steinheim, Germany and eosin; 
Merck, Darmstadt, Germany) were covered with Eukitt (O. Kindler GmbH, Freiburg, 
Germany). 
For infarct size measurement slides were scanned with highest magnification 
(3200dpi) and analysed blinded by two investigators. Using Image J Software 
(ImageJ 1.38w; http://rsbweb.nih.gov/ij/) the inner and outer outline of the left 
ventricle including the septum was measured and percentages of scar tissue was 
analysed. Additionally, cross section dimension of scar and free wall tissue of the left 
ventricle and septum were measured. 
 
 
2.9.2. Trichrome (Goldner) Staining 
 
After slices were deparaffinised in xylene and dehydrated through a graded ethanol 
series (100%, 96%, 2x80% and 2x70% EtOH), slices were incubated with 
haematoxylin for 8min, rinsed with dH2O for 10min and stained 5min with fuchsin 
acid-Ponceau (0.2g Ponceau S, 0.1g fuchsin acid in 300ml dH2O and 0.6ml acetic 
acid; Merck, Darmstadt, Germany). Slices were washed in 1% acetic acid (VWR, 
Briare, France) and incubated with phosphotungstic acid-Orange G (4g 
phosphotungstic acid and 2g Orange G in 100ml dH2O; Merck, Darmstadt, Germany) 
for 5min. 
Slices were washed again in 1% acetic acid and incubated with 1% light green 
solution (SF yellowish; Merck, Darmstadt, Germany) in 2% acetic acid for 6min. 
Finally, samples were washed and rehydrated in 80% and 100% EtOH, fixed in 
xylene and covered in Eukitt (O. Kindler GmbH, Freiburg, Germany). 
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2.9.3. TN-C Staining 
 
All sides used for IHC staining were coated with 1% poly-L-lysine (Sigma, Steinheim, 
Germany) for 15min and dried over night at 37°C.  
 
Before staining, slices were deparaffinised in xylene (Fisher Scientific, Leicestershire, 
United Kingdom) and dehydrated through a graded ethanol series (100%, 96%, 
2x80% and 2x70% EtOH). 
All slices were pretreated with 0.1% pepsin solution (Boehringer-Mannheim, 
Mannheim, Germany) in 0.01N HCL (pH 2.3; Sigma-Aldrich, Steinheim, Germany), 
for 7min at RT to retrieve the antigens. After three 10min washes in PBS, slices were 
incubated with horse blocking serum (Vectastain Elite ABC Kit, Vector Laboratories, 
Vienna, Austria) for 20min at RT. Slices were washed again three times and 
incubated overnight with primary monoclonal mouse antibody, α-human TN-C (1:10, 
IgG1, Clone 4F10TT; IBL, Hamburg, Germany) at 4°C in a wet camber. After 
overnight incubation slices were washed three times for 10min in PBS followed by 
incubation with secondary horse α-mouse-Bio antibody (3:200; Vector Laboratories, 
Burlingame, USA) for 30min at RT. Slices were washed another three times with 
PBS for 10min and incubated with ABC-Reagent (1:50; Vector Laboratories, Vienna, 
Austria) according to the manufacturer’s instructions for 30min at room temperature.  
After sections were washed three times for 10min in PBS, sections were incubated 
with diaminobenzidine (DAB) substrate Kit (Vector Laboratories, Burlingame, USA) 
for 10min to visualise positive immunoreactions. Slices were washed in dH2O, weakly 
counterstained with haematoxylin solution (Sigma, Steinheim, Germany) washed 
three times with H2O and covered in mounting medium (Dako, California, USA). 
 
20x PBS (pH 7.4):  1 liter 
2.74M NaCl (Sigma, Steinheim, Germany) 
54mM KCl (Sigma, St. Louis, USA) 
86mM Na2HPO4 (Merck, Darmstadt, Germany) 
28mM KH2PO4 (Sigma, Steinheim, Germany) 
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1x PBS (pH 7.4): 1 liter 
50ml 20x PBS 
950ml H2O 
 
 
2.10. Polyacrylamide Gel Electrophoresis and Western Blot Analysis  
 
Protean II (Bio-Rad Laboratories, Munich, Germany) equipment was used to cast two 
0.75mm thick gels. The resolving gel was poured in two phases: the first (bottom) 
phase was a plain of 7% polyacrylamide gel. For 2 gels: 3.5ml acrylamide (Serva, 
Heidelberg, Germany), 3.75ml 1.5M tris (pH 8.8; Sigma, Steinheim, Germany), 7.6ml 
ddH2O, 100µl 10% Ammonium persulfate (APS; Sigma, Steinheim, Germany), 75µl 
20% SDS (sodium dodecyl sulfate; Sigma, Steinheim, Germany), and 10µl TEMED 
(tetramethylethylenediamine; Promega, Madison, USA) were used. 
The upper stacking gel contained 625µl acrylamide, 925µl 0.5M tris (pH 6.8), 2.125ml 
ddH2O, 50µl 10% APS, 18.75µl 20% SDS, and 2.5µl TEMED. 
 
 
2.10.1. Sample Preparation 
 
Protein samples were slowly thawing on ice and diluted 1:1 with Laemmli sample 
buffer. Samples were boiled at 95°C for 10min and slowly cooled down on ice. 
15µg protein sample were subjected to 7% SDS-PAGE. Gels run at 40V for about 1h 
and 60V for ∼2h. Purified human TN-C protein (2ng) was used as positive control and 
for standardisation (Millipore, Vienna, Austria). 
 
After electrophoresis proteins were blotted with 0.04mA over night at 4°C onto a 
PVDF (Polyvinylidenfluorid) membrane (0.45µm; Millipore, Bedford, USA). Before the 
transfer started the membrane was incubated with pure methanol (Fisher Scientific, 
Leicestershire, United Kingdom) for a few seconds, 7½min in ddH2O and 7½min in 
transfer buffer. Thereafter, blotting efficiency was checked by Coomassie gel staining 
(Coomassie brilliant blue R-250; Sigma, Steinheim, Germany). Gels were incubated 
15min in staining solution followed by incubation in Coomassie destaining solution to 
visualise proteins left in the gel. 
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Unspecific binding sites on the membrane were blocked by incubation with blocking 
solution (5% low-fat dried milk powder in TBS-T; Fixmilch-Instant, Maresi, Vienna, 
Austria) on a rocking table for 1h at room temperature followed by three 10min 
washes with TBS-T.  
All blots were incubated with primary monoclonal mouse α-human TN-C antibody 
(1:100, IgG1, Clone 4F10TT; IBL, Hamburg, Germany) over night at 4°C on a rocking 
table. This antibody specifically recognised the EGF-L domains of all TN-C variants. 
After incubation the blots were washed 3 times for 10min in TBS-T.  
For detection blots were incubated with secondary goat α-mouse horseradish 
peroxidase (HRP) antibody (1:10.000; Dako, Glostrup, Denmark) in blocking solution 
for 1h at room temperature. 
After three 10min washes with TBS-T each membrane was incubated with 2ml 
freshly prepared enhanced-chemiluminescence (ECL) solution and 50µl H2O2 (GE 
Healthcare, Buckinghamshire, United Kingdom) in the dark room. Membranes were 
covered in a plastic foil and signals of immunoreactive bands were visualised by 
exposure of ECL films (GE Healthcare, Buckinghamshire, United Kingdom) for 
10sec, 30sec, 1min, 5min and 10min. 
For standardisation same membranes were washed for 1h with TBS-T, blocked 
again with blocking solution and incubated with β-actin antibody (1:2.000, clone AC-
15; Sigma, Steinheim, Germany) for 1h at room temperature. After three washing 
steps, membranes were incubated with secondary goat α-mouse HRP antibody 
(1:10.000; Dako, Glostrup, Denmark) in blocking solution for 1h at room temperature. 
Following the last washing step specific signals were displayed as mentioned before.   
 
Western blots were analysed using ImageMaster® 1D Software (Version 2.01; GE 
Healthcare, Freiburg, Germany). Quantity calibration was made using 2ng purified 
human TN-C (Chemicon/Millipore, Vienna, Austria) as standard. Amount of both TN-
C isoforms, the large and the small, was calculated separately in comparison with the 
standard curve of known value. 
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2.10.2. Buffers and Solutions 
 
10x running buffer: 1 liter 
Tris: 30.3g (Sigma, Steinheim, Germany)  
Glycine: 142.6g (Sigma, Steinheim, Germany)  
SDS: 10g 
 
10x transfer buffer: 1 liter 
Tris: 30.3g 
Glycine: 142.6g 
 
1x transfer buffer: 500ml (always fresh prepared before use) 
10x transfer buffer: 50ml 
ddH2O: 350ml 
Methanol: 100ml 
 
20x TBS-T: 1 liter  
Tris: 48.4g 
NaCl: 160g (Sigma, Steinheim, Germany) 
Tween 20: 20ml (Sigma, Steinheim, Germany) 
37% HCL: 22ml 
 
10x TBS (pH 8.0): 
Tris: 12.1g 
NaCl: 87.7g 
 
2x Laemmli sample buffer: 
125mM Tris (pH 6.8) 
4% SDS 
10% β-Mercaptoethanol (Merck, Darmstadt, Germany) 
0.002% Bromphenol blue (Merck, Darmstadt, Germany) 
20% Glycerine 
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Coomassie brilliant blue: 
0.1% Coomassie brilliant blue R-250 in destaining solution (store at RT) 
 
Coomassie destaining solution: 
Methanol: 80ml 
Acetic acid: 20ml (Merck, Darmstadt, Germany) 
H2O: 100ml 
 
 
2.11. Statistical Analysis 
 
All data within the text, figures, and tables were shown as means ± standard 
deviation (SD). For analysis of data Microsoft Excel for Mac was used. Statistical 
analysis was performed using GraphPad Prism software (Prism 4, version 4.0c for 
Mac, GraphPad Software, San Diego California USA, www.graphpad.com). 
Significant results were specified using one-way ANOVA with corresponding post hoc 
test. Dunnett´s post hoc test was selected to compare infarction groups to the control 
group. Tukey test was used to compare all groups. 
Statistical significance was achieved at a probability value of *p < 0.05. 
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3. RESULTS 
  
 
3.1. Sequencing Results 
 
Until now the sequence of the rat TN-C gene was unknown. Only a small fragment 
with about 1.856bp was published [114]. By using a total of 28 oligonucleotide TN-C 
primers (Table 3. and Figure 13.) the contiguous rat TN-C transcript was sequenced. 
This sequence (see Appendix) encompassing an open reading frame of 6.057bp that 
encodes 2.019 amino acids with a calculated molecular weight of 222kDa [115]. 
 
 
 
Figure 13. Schematic diagram of primers used for sequencing the complete rat TN-C 
cDNA (primer: Tnc-1_for to Tnc-26_rev, Tnc_rev_m+h+r and Tnc_for_m+r) and real 
time-PCR analysis (primer: Tnc_for and Tnc_rev; shown in direction from left to right: 
in green = tenascin assembly domain, yellow = epidermal growth factor like repeats, 
blue = constant fibronectin type III domains, red = alternative spliced fibronectin type 
III domains, yellow = fibrinogen globe). 
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The largest TN-C isoform, which was identified after MI, contained 5 FN-III domains 
in the alternative spliced region, called domain A1, A2, A4, B, and D (Figure 14.). 
Those 5 domains have a common size of 1.36kb. Figure 14. demonstrates primer 
used for sequencing the complete FN-III domains. 
 
 
 
 
Figure 14. Schematic diagram of primer sets used for sequencing of the alternative 
spliced FN-III domains (TA domain = tenascin assembly domain, EGF-L repeats = 
epidermal growth factor like repeats, FN-III domains = fibronectin type III domains, 
FG = fibrinogen globe). 
 
 
Four different TN-C isoforms, which are up-regulated post myocardial infarction in 
myocardial scar tissue were identified (Figure 15.). Those isoforms arise from 
alternative splicing of FN-III domains. Sizes of single FN-III domains vary between 
269bp and 274bp. In the smallest identified isoform all 5 FN-III domains (A1, A2, A4, 
B, and D) with a common size of 1.365bp were removed (Figure 16.). In one isoform 
only FN-III domain D was included and one isoform comprised domain B and D in the 
alternative spliced region.  
Rat cDNA sequence shares 94% identical residues with the murine and 83% with the 
human sequence. In comparison, rat protein sequence shares 95% identical amino 
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acids with the murine and 70% with the human TN-C sequence. 
 
 
 
 
Figure 15. PCR products of 4 identified TN-C isoforms, with 5, 2, 1, and none FN-III 
domains in the alternative spliced region, which were up-regulated 7 days post 
infarction (primer: Tnc-8_rev and Tnc-11_for; FN-III domains = fibronectin type III 
domains). 
 
 
 
 
Figure 16. Structural composition of 4 TN-C isoforms identified after myocardial 
infarction (TA domain = tenascin assembly domain, EGF-L repeats = epidermal 
growth factor like repeats, FN-III domains = fibronectin type III domains, FG = 
fibrinogen globe). 
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3.2. PCR Results 
 
PCR analysis not only showed an up-regulation of different spliced TN-C isoforms, 
moreover a time dependent shift in isoform expression was demonstrated (Figure 
17.). 
  
 
 
 
Figure 17. PCR results of scar tissue including groups of 0.5 to 14 days post 
myocardial infarction and free wall samples of sham controls (primer: Tnc-26_rev and 
Tnc-23_for were used resulting in 4 fragments with about 2.958bp, 2.128bp, 1.863bp 
and 1.593bp. GAPDH was used as control = 331bp). 
 
 
Even 12h post MI TN-C level was slightly increased, but only small isoforms (PCR 
products with 1.863bp and 1.593bp) were present. Four isoforms were identified 24 
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hours post infarction and decreased 2 days post MI, where again only the small 
isoforms were observable. Expression of the large TN-C isoform (PCR product with 
2.958bp) peaked at time point 3. Five days after infarction the large isoform was still 
present. Whereas, 7, 10, and 14 days post MI the large isoforms were down-
regulated and only small isoforms dominate. 
In contrast, within the sham group only the small isoform is slightly existent. In non-
infarcted free wall tissue of the sham control group the large isoform is completely 
absent. GAPDH was used as positive control.  
 
 
3.3. Real Time-PCR Results 
 
For real time-PCR analysis primer Tnc_for and Tnc-rev (Figure 13.), located in the 
EGF like repeats, were used resulting in a 60bp fragment. Total TN-C mRNA level 
was analysed and no determination was made between different isoforms. 
In the infarcted region real time-PCR analysis showed 12h after infarction only a 
basis level of TN-C mRNA (Figure 18.a.). Twenty-four hours post MI TN-C level was 
slightly increased. A significant TN-C mRNA up-regulation was observable 2 days 
post infarction that peaked at day 3 (day 1 vs. 2: **p < 0.01; day 1 vs. 3: ***p < 0.001) 
followed by a decrease at day 5 (day 2 vs. 5: **p < 0.01). At day 7 and 10 mRNA 
level increased again (day 0.5 vs. 7: **p < 0.01; day 5 vs. 10: *p < 0.05; day 0.5 vs. 
10: ***p < 0.001; day 1 vs. 10: *p < 0.05) and 2 weeks after infarction TN-C level was 
clearly down-regulated (day 2 vs. 14: ***p < 0.001; day 7 vs. 14: **p < 0.01; day 10 
vs. 14: ***p < 0.001) and comparable with basis level at day 0.5 after MI.  
In contrast to tissue from the infarcted region, in free wall samples of the left ventricle 
TN-C level was barely observably. Only 3 and 5 days post MI TN-C level significant 
increased (**p < 0.01; Figure 18.b.). 
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Figure 18. Real time-PCR results from (a.) scar tissue (***p < 0.001), and (b.) non-
infarcted, free wall areas (**p < 0.01) including groups of 0.5 to 14 days after 
myocardial infarction. A sham group was used as negative control. Details of results 
were described in the text. 
 
 
 
 
 
 
a) 
b) 
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3.4. Histological and Immunohistochemical Analyses 
 
In healthy, adult cardiac tissue TN-C is not expressed, but under pathological 
conditions such as myocardial infarction the protein was up-regulated within 12h. 
 
 
3.4.1. Morphometric Studies 
 
For infarct size measurement histological cross sections from time point 0.5 to 14 
days after MI were used. Table 6. summarises results from morphometrical analysis. 
Infarct size was at an average of 34.96 ± 9.17% of the left ventricle. Sham operated 
controls, without myocardial infarction, were used as negative control.  
 
 
Days post infarction Infarct size (mean ±  SD) 
0.5 30.79 ± 6.13% 
1 37.32 ± 10.60% 
2 47.08 ± 8.07% 
3 39.92 ± 7.38% 
5 28.23 ± 5.09% 
7 33.98 ± 9.01% 
10 32.12 ± 4.90% 
14 30.26 ± 5.38% 
Sham control 0% 
 
Table 6. Results from infarct size measurement of the left ventricle including groups 
of 0.5 to 14 days after myocardial infarction and a sham operated control group. 
 
 
In addition thinning of scar tissue was measured after MI (Figure 19.). Scar tissue 
diameter peaked at day 2 post infarction (day 0.5 vs. 2: **p < 0.01). Starting 5 days 
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post MI significant thinning of the left ventricle was noticeable (day 2 vs. 5, 10 and 
14: ***p < 0.001; day 2 vs. 7: **p < 0.01; day 3 vs. 5: *p < 0.05; day 3 vs. 14: **p < 
0.01).  
Cross sections of septum samples including groups of 0.5 to 14 days post infarction 
showed no difference compared to sham controls  (p = ns; Figure 20.).  
 
 
 
 
 
Figure 19. Results from scar cross section measurement including groups of 0.5 to 
14 days after myocardial infarction and a sham operated control group (***p < 0.001). 
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Figure 20. Results from septum cross section measurement including groups of 0.5 
to 14 days after myocardial infarction and a sham operated control group (p = ns). 
 
 
Cross sections taken from sham operated control animals were completely negative 
for TN-C staining (Figure 21.c.). Twelve hours after MI little amounts of TN-C protein 
were noticeable in the border zone between infarcted and non-infarcted regions 
(Figure 21.f. and 24.b.). Twenty-four hours post infarction (Figure 21.i.) TN-C protein 
level increased, peaked at day 7 (Figure 23.c.) after MI and than slightly decreased 
at time point 10 and 14 (Figure 23.f. and i.). Two weeks post MI a collagen based 
solid scar is formed (Figure 23.g., h., and i.). 
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Figure 21. (a., d., and g.) H&E staining, (b., e., and h.) Trichrome (Goldner) staining, 
and (c., f., and i.) TN-C staining. (a., b., and c.) Sham control, (d., e., and f.) 12 
hours, and (g., h., and i.) 24 hours post myocardial infarction. 
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Figure 22. (a., d., and g.) H&E staining, (b., e., and h.) Trichrome (Goldner) staining, 
and (c., f., and i.) TN-C staining. (a., b., and c.) 2 days, (d., e., and f.) 3 days, and 
(g., h., and i.) 5 days post myocardial infarction. 
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Figure 23. (a., d., and g.) H&E staining, (b., e., and h.) Trichrome (Goldner) staining, 
and (c., f., and i.) TN-C staining. (a., b., and c.) 7 days, (d., e., and f.) 10 days, and 
(g., h., and i.) 14 days post myocardial infarction. 
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3.4.2. TN-C and Trichrome (Goldner) Staining 
 
 
At time points 0.5 to 2 days post infarction TN-C protein was slightly present in the 
border zone, whereas the infarcted region was complete negative for TN-C staining 
(Figure 24.b. and c., Figure 25.b. and c., black arrows).  
Trichrome (Goldner) staining demonstrates total collagen deposition (shown in light 
green). From 2 to 3 days post infarction collagen fibre accumulation was observed in 
the infarcted region (Figure 25.a., and Figure 26.a.).  
Three days post MI TN-C staining slightly increased in the marginal zone and the 
infarcted area was still TN-C negative (Figure 26.b., black arrows). 
 
 
 
 
 
Figure 24. (a.) Trichrome (Goldner) staining, and (b. and c.) TN-C staining 12 hours 
post myocardial infarction. (c.) Enlarged image of serial sections. 
 
   
a) b) 
c) 
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Figure 25. (a.) Trichrome (Goldner) staining, and (b. and c.) TN-C staining 2 days 
post infarction (black arrows). (c.) Enlarged image of serial sections. 
   
 
 
 
 
a) 
b) 
c) 
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Figure 26. (a.) Trichrome (Goldner) staining, and (b.) TN-C staining 3 days after 
myocardial infarction (black arrows).  
 
 
Five days after MI collagen staining was still positive within the infarcted region but 
prominent shifted in the border zone between infarcted and non-infarcted region 
(Figure 27.a. and c.). 
 
Interestingly, at day 5 and 7 post MI TN-C staining and collagen staining showed a 
very similar localisation pattern within the border zone (Figure 27. and Figure 28.). At 
day 7 post MI TN-C staining reached the maximum level (Figure 28.b., d., and f.). 
Seven days post infarction TN-C was expressed around healthy cardiomyocytes in 
areas where infiltrations were located (Figure 29.a. and b.). 
 
 
a) b) 
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Figure 27. (a. and c.) Trichrome (Goldner) staining, and (b. and d.) TN-C staining 5 
days post myocardial infarction. (c. and d.) Enlarged images of serial sections of the 
myocardial infarction border zone. 
 
 
 
 
Continued on next page. 
a) b) 
c) d) 
a) b) 
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Figure 28. (a., c., and e.) Trichrome (Goldner) staining, and (b., d., and f.) TN-C 
staining 7 days post myocardial infarction. (c., e., d., and f.) Enlarged images of 
serial sections of the myocardial infarction border zone. 
 
 
 
 
Figure 29. (a. and b.) TN-C staining 7 days post myocardial infarction. (b.) Enlarged 
image of serial section.  
 
c) d) 
e) f) 
a) b) 
 Results  
 
 
 80 
 
 
Figure 30. (a. and c.) Trichrome (Goldner) staining, and (b. and d.) TN-C staining 10 
days after myocardial infarction. 
 
 
 
 
Figure 31. (a.) Trichrome (Goldner) staining, and (b.) TN-C staining 2 weeks after 
myocardial infarction. 
 
a) b) 
c) d) 
a) b) 
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Ten days after MI collagen fibre accumulation was mainly visible in the border zone 
(Figure 30.a. and c.) and TN-C protein level clearly decreased (Figure 30.b. and d.). 
Therefore, 14 days post infarction TN-C expression was only slightly visible in the 
border zone between infarcted and non-infarcted areas (Figure 31.b.). Within the 
sham control group no TN-C expression was detectable at all (Figure 32.b.). 
 
 
 
 
Figure 32. (a.) Trichrome (Goldner) staining, and (b.) TN-C staining of sham 
controls. 
 
 
3.4.3. TN-C Staining of Control Organs 
 
TN-C expression pattern was analysed within kidney, liver, lung, and spleen tissues. 
Protein distribution 7 days after infarction was compared to sham controls.  
TN-C staining of kidneys from sham controls was positive for TN-C (Figure 33.a.). 
Kidney medulla showed TN-C immunoreactivity in the tubule interstitial spaces. TN-C 
level 7 days post MI increased compared to controls (Figure 33.b.)  
Normal liver samples showed weak, discontinuous sinusoidal TN-C staining (Figure 
34.a.). Staining of liver tissue 7 days post MI showed more TN-C positive (Figure 
34.b.) areas compared to the sham control group. 
Normal tissue samples from rat lungs (Figure 35.a.) and 7 days post infarction 
(Figure 35.b., black arrows) were barely positive for TN-C staining. 
a) b) 
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Spleens showed positive TN-C staining in the marginal zones and the capillaries of 
both groups, 7 days after infarction (Figure 36.b. and c., black arrow) and sham 
controls (Figure 36.a.). 
 
 
 
 
Figure 33. TN-C staining of kidney tissue from (a.) sham control, and (b.) 7 days 
post myocardial infarction. 
 
 
 
 
Figure 34. TN-C staining of liver tissue from (a.) sham control, and (b.) 7 days post 
myocardial infarction. 
 
 
 
 
a) b) 
a) b) 
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Figure 35. TN-C staining of lung tissue from (a.) sham control, and (b.) 7 days post 
myocardial infarction (black arrow). 
 
 
 
 
 
Figure 36. TN-C staining of spleen tissue form (a.) sham control, and (b. and c.) 7 
days post myocardial infarction (black arrow). (c.) Enlarged image of serial section. 
 
a) b) 
a) b) 
c) 
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3.5. Western Blot Results 
 
Western blots were loaded with myocardial tissue lysates (15µg) isolated from scar 
tissue including time points 0.5 to 14 days post MI. Free wall samples of the left 
ventricle of sham controls were used as negative control and β-actin was used as 
loading control. Purified human TN-C, which migrates around 280-300kDa, was used 
as positive control and for standardisation. 
 
In western blot experiments especially two different TN-C isoforms were detectable in 
the infarcted area of the left ventricle post MI. Those isoforms have an apparent 
molecular weight of 230kDa and 270kDa.  
A time dependent shift and, additionally, a shift in TN-C isoform expression were 
observable.  
Twelve hours to 14 days after MI the smaller isoform was slightly detectable in the 
infarcted region, but no significant differences were observed in comparison to the 
sham control group (p = ns; Figure 37.a.).  
In contrast to the expression of the small TN-C isoform, 12h and 24h post infarction 
the larger isoform was not present (Figure 37.b.). The larger TN-C isoform was 
observable 2 days after infarction, TN-C level increased at day 3 (day 0.5 and 1 vs. 
3: **p < 0.01; day 3 vs. sham control: ***p < 0.001), and peaked 5 days post MI (day 
0.5 and 1 vs. 5: ***p < 0.001; day 2 vs. 5: **p < 0.01). At this time point the larger 
isoform is 5-fold up-regulated compared to 2 days post infarction. After day 5 (day 5 
vs. 10: **p < 0.01; day 5 vs. 14: *p < 0.05; day 5 vs. sham control: ***p < 0.001) and 
day 7 post infarction (day 7 vs. sham control: **p < 0.01; day 0.5 and 1 vs. 7: *p < 
0.05) the large TN-C isoform was still present but level decreased. At day 10 and 14 
post MI only marginal amounts of the large TN-C isoform were present.  
In the sham control group from non-infarcted free wall samples of the left ventricle, 
no expression of the large TN-C isoform was detectable. 
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Figure 37. Results from western blot analysis of (a.) small (p = ns), and (b.) large 
(**p < 0.01 and *p < 0.05) TN-C isoforms including groups of 0.5 to 14 days after 
myocardial infarction. Free wall tissue from the sham group was used as negative 
control. Details of results were described in the text. 
  
 
b) 
a) 
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4. DISCUSSION 
 
 
4.1. Sequencing Results 
 
TN-C is a large hexameric molecule composed of multiple domains. Each domain 
binds to different cell surface receptors, including integrins and ECM components, 
such as fibronectin. Those interactions influence different cellular programs and 
functions. Isoforms differ in number of FN-III domains in the alternative spliced 
region. Small isoforms with no or only a few FN-III domains in the splicing region are 
often in association with embryonic development and organogenesis. In contrast, 
large isoforms are up-regulated under pathologic conditions [44]. 
So far human [116] and murine [117] TN-C cDNA and associated protein amino acid 
sequence were known. In this project rat cDNA sequence was analysed, 
encompassing an open reading frame of 6.057bp that encodes 2.019 amino acids 
with a calculated molecular weight of 222kDa. 
In contrast, encoded human TN-C protein contains a total of 2.203 amino acids [116], 
whereas the murine protein sequence [117], similarly to the rat sequence, includes 
2.019 amino acids. 
Sequence identity in the alternative spliced FN-III domains varies a lot. In mouse 
tissues they share 52% of their nucleotide sequence on average. The lowest degree 
of similarity is recorded between FN-III domain A2 and D (41%), and the highest 
between domain A1 and A4 (80%) [118].  
 
Four isoforms were detected and identified in the infarcted region after myocardial 
infarction. The largest of those isoforms include 5 FN-III domains in the alternative 
spliced region called A1, A2, A4, B, and D. Additionally isoforms with 2 (domain B 
and D), 1 (domain D), and none FN-III domains in the splicing region were identified 
(Figure 16.).  
Especially those isoforms including FN-III domains B and/or D arise in a variety of 
different and multifaceted diseases. 
In human invasive and pre-invasive breast disease mainly 2 isoforms were detected. 
Those variants included FN-III domain B and D, or only domain D [119]. Additionally, 
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a subset of ductal carcinoma in situ (DCIS) cases were also found to express these 
TN-C isoforms, which may be indicative of a high risk of invasion in these lesions.  
Both TN-C variants, containing FN-III domains B and D, or only domain D, were also 
detected post infarction. 
Furthermore, under pathologic conditions in a mouse model of habu snake venom 
(HSV) induced glomerulonephritis it was demonstrated that in particular, isoforms 
containing FN-III domain D are the major components of both healthy and 
pathological kidney. In contrast, domain C may not play an important role in the 
progress of HSV-induced glomerulonephritis [118]. 
 
However, the large isoform with 5 domains indicate a special role in myocardial 
remodelling, because large isoforms were associated with pathological conditions. To 
date FN-III domains AD1, AD2, and A3 have not been detected in the rat heart post 
MI. 
From an evolutionary point of view, the availability of rodent TN-C domains 
equivalent to FN-III domains AD1 and AD2 is highly probable, because both domains 
were identified in human as well as in avian TN-C variants. These findings may 
suggest that both domains arose from duplication processes that occurred before the 
avian and mammalian species diverged. Therefore, both AD domains should be 
present in rodents as well. In contrast, the different FN-III A domains (A1, A2, A3, 
and A4) found in mammals presumably evolved later. In particular, domain A3 has 
only been detected in human TN-C and might be unique for primate TN-C variants 
[47]. Nevertheless further studies are required to analyse different TN-C domains, 
especially their binding interactions and functions.  
 
Comparing fibronectin to TN-C it can be said that both consist of large disulfide-
linked subunits composed of multiple structural domains and more than half of each 
molecule consists of FN-III domains, but the other domains differ a lot. Fibronectin is 
a dimeric molecule, whereas TN-C is a hexamer. Often both molecules are 
colocalised in tissues, but the occurrence of TN is much more restricted when 
compared with fibronectin [120].  
Whereas fibronectin mediates mainly cell adhesion via destined integrins and 
proteoglycans, TN-C influences deadhesion of cells. One mechanism of TN-C to 
modulate cell adhesion is the blocking of cell attachment to fibronectin [57]. 
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In human myocardial scars similar to TN-C, cardiac fibroblasts are the major source 
of fibronectin [67]. After injury fibronectin is present within 4 hours and increased at 
48 hours. This early activation is thought to influence inflammatory, fibrotic and 
angiogenetic processes involved in wound healing. In mature myocardial scar tissue 
fibronectin is absent. 
 
 
4.2. PCR Results 
 
In tissue samples after myocardial infarction PCR analysis demonstrated a clear shift 
in TN-C isoform expression. Already 12 hours post infarction the small TN-C variant 
was slightly up-regulated (Figure 17.). The large variant, containing FN-III domains 
A1, A2, A4, B, and D (Figure 16.), peaked at day 3. Down-regulation started at day 7 
after MI. In the sham control group only the small isoform was barely present (Figure 
17.). 
These results were in agreement with further studies, demonstrating a correlation 
with pathologic events and specific TN-C domains and isoforms [64, 118, 121]. 
Unfortunately, most studies determine this accordance in the field of tumour biology. 
Therefore, the detection of different spliced FN-III domains could be useful for 
assessment of invasiveness, tumour surveillance, as well as target structures for 
antibody based tumour detection and therapy [64, 119, 122, 123].  
For instance, analysis of tissue samples from cutaneous squamous cell carcinoma 
and the precursor lesion actinic keratosis demonstrated that TN-C isoforms were 
specific up-regulated under pathologic conditions [122]. The large variant was 
present under both circumstances in comparison to normal skin samples, which were 
nearly negative for the large isoform.  
However, the knowledge of up-regulated different TN-C isoforms in the failing heart 
could be a potent therapy approach. 
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4.3. Real Time-PCR Results 
 
Real Time-PCR demonstrated a clear shift in TN-C expression after myocardial 
infarction. In the infarcted area 12h after infarction only a basis level of TN-C mRNA 
(Figure 18.a.) was present. Twenty-four hours after infarction TN-C level was slightly 
increased. Whereas a significant TN-C up-regulation was observable 2 days post MI 
that peaked at day 3 followed by a decrease at day 5. One week to 10 days post 
infarction mRNA level increased again and 14 days after MI TN-C protein level was 
comparable with basis level 12h after MI. In contrast to tissue from the infarcted 
region, tissue samples of free walls showed only barely mRNA appearance. Only 3 
and 5 days post MI TN-C level slightly present (Figure 18.b.). From these results it 
can be concluded that TN-C plays an important role in the early phase of post 
myocardial infarction remodelling, and additionally, that TN-C protein expression is 
restricted to the infarcted region. 
 
Studies from mouse central nervous system showed that TN-C isoform expression 
shifted in brain organogenesis [47]. TN-C expression peaked around P0 and 
decreased toward the second postnatal week. In adult brain tissue, only small 
isoforms persist. The signals obtained with the probes detecting FN-III domains A1 
and A2 peaked at P0, whereas the signals for the domains C and D reached the 
maximal level at E16, suggesting that different TN-C variants might be expressed at 
different developmental stages.   
 
 
4.4. Histological and Immunohistochemical Analysis 
 
 
4.4.1. Morphometric Studies 
  
Sudden induction of ischemia by occlusion of coronary arteries triggers a series of 
events including death of ischemic cardiomyocytes. Cardiomyocyte necrosis 
activates an inflammatory cascade that serves to clear the infarcted area of dead 
cells and matrix debris, resulting in rearrangement and healing of the damaged tissue 
within scar [124].  
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After MI heart structure and geometry are affected as well as composition of 
myocardial tissue components is impaired. Post infarction heart shows remarkable 
capacity to adapt to the new conditions of the left ventricle. After infarction a 2- to 3-
fold increase in myocardial collagen above the normal level results in increased LV 
stiffness and mild dysfunction. Even a very small decrease in collagen below normal 
can lead to drastic consequences, including LV dilation, and rupture [30]. 
 
In this study only individuals with an infarct size of ≥ 20% of the left ventricle were 
included. Measured infarction size was similarly in all infarction groups (Table 6.). 
Left ventricular wall thinning was already detectable 5 days post MI (Figure 19. and 
Figure 22.g., h., and i.). Furthermore 10 to 14 days after MI, thinning of the infarcted 
area was clearly observable (Figure 19. and Figure 23.d.-i.). Therefore, structure and 
geometry of the left ventricle was dramatically changed in comparison to the healthy 
sham control (Figure 21.a., b., and c.). 
It was reported that rearrangement of groups or bundles of myocytes results in 
decreased cell number across the ventricular wall [125]. This new organisation 
accounts for most wall thinning in the infarcted area and all thinning in non-infarcted 
regions. In non-infarcted regions, cell slippage accounts for all thinning. Cell stretch 
and loss of intercellular space are confined to the infarcted area and contribute less 
to wall thinning than does cell slippage. 
 
 
4.4.2. TN-C and Trichrome (Goldner) Staining 
  
 
A detailed descriptive analysis of the time course of TN-C deposition in healing 
myocardial infarcts is crucial to understand the role and function of this matricellular 
protein in cardiac healing after injury. Especially, the mechanisms responsible for TN-
C induction in the infarcted area still remain unknown. Cytokines and growth factors, 
such as TNF-α, TGF-β, and bFGF, released in healing myocardial tissue stimulate 
fibroblast TN-C synthesis [126]. In addition, angiotensin II, an important regulator of 
cardiac remodelling and fibrous tissue deposition, is also known to influence TN-C 
expression [126]. The role of TN-C in infarct healing and remodelling remains 
unknown.  
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Results from this study are in agreement with further studies that demonstrated that 
during healing process after MI, TN-C protein and TN-C producing cells were found 
at the edges of the residual myocardium [85].  
TN-C protein deposition appeared in the border zone within 12 hours after permanent 
coronary ligation (Figure 24.b. and c.). Seven days post infarction protein deposition 
peaked (Figure 28.b., d., and f.) and down regulation started 10 days post MI (Figure 
30.b. and d.). Two weeks post infarction TN-C protein expression was only slightly 
visible in the border zone between infarcted and non-infarcted region (Figure 31.b.). 
Seven days after infarction TN-C was present around healthy cardiomyocytes 
surrounded by infiltrated areas (Figure 29.).  
Such transient up-regulation of TNC is consistent with the previous 
immunohistochemical findings for human infarcted myocardium [67]. In human 
healing myocardial scars TN-C was found 4-6 days post infarction and was located at 
the margin of the area of infarction. TN-C was present until 2-3 weeks after MI and 4 
weeks post MI TN-C expression had disappeared completely. 
This selectively expression in the border zone, between infarcted and non-infarcted 
areas suggests that it may be important in the dynamic events associated with 
cardiac remodelling following myocardial injury.  
 
TN-C may not only modulate attachment of cardiomyocyte on the ECM, but may also 
play multiple roles in myocardial tissue remodelling to control interstitial cell 
behaviour during repair of tissue damage [85].  
As reported before, TN-C is synthesised during the acute and early phase after 
infarction by interstitial cells in the border zone [85]. This early expression of TN-C 
after tissue injury is related to cell migration and proliferation. Therefore it can be 
concluded that TN-C act as a de-adhesive adapter molecule. TN-C may loosen the 
strong adhesion of surviving cardiomyocytes to connective tissue and thereby 
facilitate tissue reorganisation. TN-C expression virtually disappears in the mature 
scar tissue. 
In addition, a recent study examined the effects of TN-C deficiency in a model of 
electrical cardiac injury [92]. It was demonstrated that TN-C null mice exhibit delayed 
recruitment of myofibroblasts in the injured myocardial site indicating that TN-C 
promotes recruitment of myofibroblasts in the early stages of myocardial repair by 
stimulating cell migration and as well cell differentiation. 
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Furthermore, the myocardial collagen meshwork is damaged after myocardial injury. 
The extent of collagen damage correlates with the degree of infarct expansion [127]. 
Post infarction several endogenous molecules that affect collagen synthesis are up-
regulated. Those molecules include bradykinin, TNF-α, IL-1, INF-γ, and several 
agents that are used therapeutically, affect collagen turnover and be considered as 
anti-fibrotic [30]. After infarction collagen molecules were newly synthesised and 
embedded in scar tissue. This can potentially alter ECM remodelling in the infarcted 
region and impair the healing process [30]. 
The major cardiac fibrillar collagens are types I and III. In the human heart 85% of 
total collagen is type I, which is associated mainly with thick fibres that confer tensile 
strength and resistance to stretch and deformation. In contrast, only about 11% of 
total collagen is type III, which is associated with thin fibres that confer resilience. 
The synthesis of collagens is slow compared to non-collagen proteins and the 80- to 
120-day half-life of collagen is 10 times longer than that for non-collagen proteins. 
Therefore, replacement of collagen fibres after degradation of ECM components 
occurs very slowly. This long time frame includes the potential vulnerability for 
harmful remodelling events in conditions associated with increased ECM degradation 
such as acute MI [30].  
 
In this study, Trichrome (Goldner) staining showed an overview of collagen fibre 
accumulation in the centre of the forming scar until day 2 post infarction. Five days 
after MI collagen formation was observed in the infarcted area and in the border 
zone. Collagen fibres were degraded and new fibres were synthesised to strengthen 
the forming scar tissue after injury. This controlled and regulated degradation of ECM 
components post MI is a critical step for growth, remodelling, rearrangement, repair, 
and healing processes. This events are mainly regulated by MMPs and their 
counterparts the TIMPs [30]. 
 
 
4.4.3. TN-C Staining of Control Organs 
 
As well as in myocardial tissue, TN-C is up-regulated under pathologic conditions in 
other tissues. Vascular smooth muscle cells and endothelial cells of various organs 
have the potential to synthesise TN-C. It was demonstrated for a diversity of 
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pathologies such as MI [91] or CHC [107] that serum TN-C levels were increased. 
Those high levels of circulating TN-C may influence other organs.  
Furthermore, elevated levels of circulating inflammatory mediators in heart failure 
might also stimulate endothelial cells of, for example, the liver, to secrete TN-C into 
the blood stream [98]. 
 
In this study TN-C protein deposit was analysed in kidney, liver, lung, and spleen 
tissues 7 days post infarction and compared to the sham control group (Figure 33.- 
36.). An increased TN-C level was observed only in kidney and liver tissues post 
infarction (Figure 33. and 34.). Further studies are needed to demonstrate if TN-C 
expression was up-regulated after MI in liver and kidney tissues or if circulating TN-C 
accumulates in those organs. 
 
Studies showed that TN-C is involved in liver fibrosis in CHC patients [128]. Large 
variants were not expressed in normal liver tissue, but were up-regulated in CHC, 
especially at sites of interface hepatitis and confluent necrosis, TN-C and its variants 
are produced by hepatic stellate cells (HSCs)/myofibroblasts. 
TN-C staining in normal liver samples is positive with the 4F10TT antibody 
recognising the EGF-L repeats of all TN-C variants, which was used as well in this 
study. In contrast, normal liver samples are negative for the TN-C antibody 6C6MS, 
which recognise the FN-III domain C included in the large TN-C isoform. Liver 
samples from patients with CHC are positive for both antibodies. Additional serum 
TN-C is a useful marker of the activity of CHC, in particular of the degree of 
piecemeal necrosis [107]. 
 
Normal tissue samples from rat lungs (Figure 35.a.) are barely positive for TN-C 
staining [129]. Whereas, TN-C expression increased during pulmonary injury induced 
by intratracheal bleomycin instillation. After initial lung injury TN-C was primarily 
present during the early inflammatory phase [129] . 
 
Within spleen tissue TN-C was found to be an ECM component at all developmental 
ages as well as in adults. Especially, ring fibres, which are modified basement 
membranes around venous sinuses, were positive for TN-C [130].  
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In kidneys from adult mice, no TN-C can be found in the cortex, but interspersed 
patches of staining are visible in the medullary stroma [131]. In a mouse model of 
HSV induced glomerulonephritis it was shown that TN-C was up-regulated under 
pathologic conditions in the kidney [118].  
 
 
4.5. Western Blot Results 
  
Western blot analysis showed a clear shift in TN-C isoform expression. As known, 
larger TN-C isoforms are prominent under pathologic conditions where remodelling 
occur. So it is not surprising, that larger isoforms were up-regulated in the infarcted 
region.  
Similar results were obtained in other tissues, such as kidneys. After 
glomerulonephritis 2 isoforms were up-regulated in kidney after injury [118]. 
 
In myocardial tissue the small TN-C isoform was present within 12 hours and showed 
no significant change until 2 weeks post MI compared to the sham control group 
(Figure 37.a.).  
In contrast, 12 to 24 hours after infarction the large isoform were not existent in scar 
tissue (Figure 37.b.). Large TN-C isoform up-regulation started at day 2 post MI and 
peaked at day 5. After day 5 post infarction large TN-C isoform level decreased and 
protein was only marginal present 2 weeks after infarction.  
TN-C fragments smaller than 230kDa were presumably degraded molecules [105]. 
TN-C and members of the MMP family, which play an important role in TN-C 
degradation, are reciprocal regulated. TN-C influences expression and activity of 
MMPs, leading to a changed composition of the preexisting ECM. This altered tissue 
microenvironment influences cellular adhesion, cell motility, growth, survival, and/or 
differentiation [5]. 
 
From this results can be concluded, that larger isoforms play an important, even if not 
totally understood, role in the first phase of remodelling post infarction. Even if 
western blot analysis not allowed detailed separation of all single TN-C isoforms a 
clear shift was observable and gives a clue that TN-C plays in the dynamic process 
of cardiac remodelling an important role. 
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4.6. Knockout Mice  
 
Knockout mice are important animal models to study the specific gene inactivation 
and give a clue for role and function of turned off proteins. Until now, TN-C [93], TN-
R [132] and TN-X [133] deficient mice have been generated. Interestingly, TN-X null 
mice show similar symptoms as in the human Ehlers-Danlos syndrome, confirming a 
causative role for this gene in this disease [36]. 
Additionally, double knockouts lacking TN-C/TN-X [134] and TN-C/TN-R [135] have 
been generated. 
TN-C knockout mice, generated in 1992 have no demonstrative phenotypic defects 
[93]. They were born alive, were fertile but their behaviour was markedly abnormal 
[136]. Mice showed hyper locomotion, stereotyped turning behaviour, and poor 
swimming ability resulting from altered levels of neurotransmission in brain chemistry 
[137]. This abnormal behaviour and movements of TN knockout mice is similar to 
Rett’s syndrome. 
 
Healing of cutaneous wounds in TN-C deficient mice was analysed [138]. Skin 
wounds only showed a diminished fibronectin expression in those mice. Surprisingly, 
the reduced amount of fibronectin has no influence on the quality of the healing 
process. These findings would be interesting in combination with healing of 
myocardial scars after myocardial infarction. Therefore, it would be interesting to 
check the role of TN-C in the healing scar post MI in TN-C knockout mice. 
 
Furthermore the role of two other members of the matricellular protein family, OPN 
[139] and TSP2 [140] has been investigated after infarction in their respective null 
mice. The OPN as well as the TSP2 deficient mice showed a clear phenotype after 
MI. The OPN null mice had an exaggerated left ventricle dilatation, whereas more 
than 90% of the TSP2 null mice died after infarction due to cardiac rupture.  
These data demonstrate that both matricellular proteins are necessary to maintain a 
normal cardiac structure and function after myocardial injury. 
 
The relatively mild developmental phenotypes described in TN-C knockout mice [93] 
might be explained by functional redundancy within the TN family but, as yet, there is 
no evidence that the expression pattern of one TN changes in response to the 
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knockout of another TN molecule [40].  
Potential candidates for this compensatory effect are other members of the TN 
family, although the expression patterns of identified members of this family show 
only partial overlap [40, 132]. For example the compensatory effect of TN-X and TN-
C in skin tissue [141].  
This leaves open the possibility that an uncharacterised TN could be present in the 
ECM and assume this role [40].  
 
 
4.7. Tenascin-C - A Potential New Biomarker? 
 
Searching for new biomarkers, which are more sensitive and specific a lot of 
candidates were found. Promising potent markers for MI and acute cardiac diseases 
may be sCD40, myeloperoxidase, ischemia-modified albumin, pregnancy-associated 
plasma protein-A, choline, placental growth factor, cystatin C and fatty acid binding 
protein [78].  
In this context it was reported previously, that serum TN-C might also be a novel 
biomarker for myocardial injury and the remodelling process post acute MI [91]. For 
instance, patients with IDC showed a significant higher serum TN-C level compared 
to the control group. Additionally, patients with terminal heart failure showed a 
significant elevated TN-C serum level [142]. Those elevated TN-C levels were 
significantly associated with the New York Heart Association (NYHA) functional 
class, left ventricular ejection fraction (EF), left ventricular end-systolic diameter and 
BNP level. Moreover, a positive correlation between TN-C level and troponin T level 
was shown, indicating that circulating TN-C is generally associated with the severity 
of left ventricular dysfunction [97]. 
 
Most reports show an association with TN-C expression and tumour development. In 
various types of carcinomas TN-C expression correlates with angiogenesis and local 
infiltration [99]. 
Even those available studies often do not distinguish between the many different TN-
C splicing variants that exist. However, only some studies show that certain isoforms 
may be more frequent under specific pathologic conditions than in normal and 
healthy tissues [123]. Thus, a detailed distinction between TN-C splice variants and 
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description of different FN-III domains in the alternative spliced region may enable a 
more precise interpretation. 
 
It was shown that tumour-targeting antibodies against the alternative spliced FN-III 
domains A1 and D of the large TN-C isoform, which accumulates at tumour rich sites, 
are promising building blocks for the development of antibody-based 
pharmaceuticals [100]. 
For radio-immunotherapy in patients with newly diagnosed malignant tumours β-
particle-emitting 131I-labeld anti-TN-C antibodies were used in a phase-II trail showing 
promising results [101, 143]. In another study α-emitting 211At-labeld anti-TN-C 
antibodies were used for regional targeted radiotherapy, showing anti-tumour 
benefits in patients with malignant central nervous system tumours [144]. 
 
Taken together, TN-C is a very useful marker for the early phases of connective 
tissue remodelling associated with many pathologies, such as tumour development 
or MI. An early inflammatory response is in the majority of cases associated with 
enhanced TN-C levels, both in the tissue and in plasma.  
However, since some highly malignant tumours seem to lose TN-C expression during 
progression, caution is required to use TN-C as a marker for diagnosis. 
Nevertheless, in certain instances this molecule has proven its value as a convenient 
diagnostic tool and perhaps even for the treatment of cancer.  
However, to reach the full diagnostic and therapeutic potential, more basic research 
is needed to clarify the precise function and gene regulation of TN-C. 
 
 
4.8. Limitations of the Study 
 
The remodelling process post infarction is very dynamic and only eight time points 
after infarction were included in this study to provide an insight into this event. Those 
selected time points represents just snap shots in this process. 
The small sample size is another study limitation. 
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5. CONCLUSION 
 
 
Taken together, small TN-C isoforms, with few or none FN-III domains in the 
alternative spliced region, are in association with the normal and healthy ECM. In 
contrast, large TN-C isoforms are up-regulated in many tissues under pathologic 
conditions. 
 
After sequencing the complete rat TN-C cDNA, four different TN-C isoforms were 
identified, which are present in the heart after myocardial infarction. Those isoforms 
differ in size because of alternative splicing processes within the fibronectin-III (FN-
III) domain. 
Arising isoforms include 5, 2, 1, and none FN-III domains in the alternative spliced 
region. Interestingly, the large TN-C isoform was only present very short in the early 
remodelling phase post infarction. 
 
This study demonstrates a time dependent TN-C up-regulation post myocardial 
infarction and, additionally, a shift in TN-C isoform expression post MI. This time 
dependent shift in TN-C isoform expression indicates a special role for FN-III 
domains.  
Further experimental studies are necessary to show precise function of distinct 
domains in different spliced TN-C variants. So TN-C may serve as a useful biomarker 
in cardiovascular diseases.  
 
 
 
 
 
 
 
 
 
 
____________________________________________________________________ 
 
 100 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 References  
 
 
 101 
6. REFERENCES 
 
1. Bornstein P and Sage H E, Matricellular proteins: extracellular modulators of 
cell function. Curr Opin Cell Biol, 2002. 14(5): p. 608-616. 
2. Murphy-Ullrich J E, The de-adhesive activity of matricellular proteins: is 
intermediate cell adhesion an adaptive state? J Clin Invest, 2001. 107(7): p. 
785-790. 
3. Schellings M W M, Pinto Y M and Heymans S, Matricellular proteins in the 
heart: possible role during stress and remodeling. Cardiovasc Res, 2004. 
64(1): p. 24-31. 
4. Henry H C and Schwarzbauer J E, Meet the Tenascins: Multifunctional and 
Mysterious. J Biol Chem, 2005. 280(29): p. 26641-26644. 
5. Jones F S and Jones P L, The tenascin family of ECM glycoproteins: 
structure, function, and regulation during embryonic development and tissue 
remodeling. Dev Dyn, 2000. 218(2): p. 235-259. 
6. Chiquet-Ehrismann R, Mackie E J, Pearson C A and Sakakura T, Tenascin: 
an extracellular matrix protein involved in tissue interactions during fetal 
development and oncogenesis. Cell, 1986. 47(1): p. 131-139. 
7. Mackie E J, Molecules in focus: tenascin-C. Int J Biochem & Cell Biol, 1997. 
29(10): p. 1133-1137. 
8. Bourdon M A, Wikstrand C J, Furthmayr H, Matthews T J, et al., Human 
glioma-mesenchymal extracellular matrix antigen defined by monoclonal 
antibody. Cancer Res, 1983. 43(6): p. 2796-2805. 
9. Chiquet M and Fambrough D, Chick myotendinous antigen. I. A monoclonal 
antibody as a marker for tendon and muscle morphogenesis. J Cell Biol, 1984. 
98(6): p. 1937-1946. 
10. Chiquet M and Fambrough D M, Chick myotendinous antigen. II. A novel 
extracellular glycoprotein complex consisting of large disulfide-linked subunits. 
J Cell Biol, 1984. 98(6): p. 1937-1946. 
11. Erickson H P and Inglesias J L, A six-armed oligomer isolated from cell 
surface fibronectin preparations. Nature, 1984. 311(5983): p. 267-269. 
12. Grumet M, Hoffman S, Crossin K L and Edelman G M, Cytotactin, an 
extracellular matrix protein of neural and non-neural tissues that mediates glia-
neuron interaction. Proc Natl Acad Sci U S A, 1985. 82(23): p. 8075-8079. 
 References  
 
 
 102 
13. Kruse J, Keilhauer G, Faissner A, Timpl R, et al., The J1 glycoprotein - a novel 
nervous system cell adhesion molecule of the L2/HNK-1 family. Nature, 1985. 
316(6024): p. 146-148. 
14. Rettig W J and Garin-Chesa P, Cell type-specific control of human 
neuronectin secretion by polypeptide mediators and phorbol ester. J 
Histochem Cytochem, 1989. 37(12): p. 1777-1786. 
15. Erickson H E and Taylor H C, Hexabrachion proteins in embryonic chicken 
tissues and human tumors. J Cell Biol, 1987. 105(3): p. 1387-1394. 
16. Hoffman S, Crossin K L  and Edelman G M, Molecular forms, binding 
functions, and developmental expression patterns of cytotactin and cytotactin-
binding proteoglycan, an interactive pair of extracellular matrix molecules. J 
Cell Biol, 1988. 106(2): p. 519-532. 
17. Aufderheide E and Ekblom P, Tenascin during gut development: Appearance 
in the mesenchyme, shift in molecular forms, and dependence on epithelial-
mesenchymal interactions. J Cell Biol, 1988. 107(6): p. 2341-2349. 
18. Järvinen T A H, Kannus P, Järvinen T L N, Jozsa L, et al., Tenascin-C in the 
pathobiology and healing process of musculoskeletal tissue injury. Scand J 
Med Sci Sports, 2000. 10(6): p. 376-382. 
19. Gullberg D, Velling T, Sjöberg G, Salmivirta K, et al., Tenascin-C expression 
correlates with macrophage invasion in Duchenne muscular dystrophy and in 
myositis Neuromuscul Disord, 1997. 7(1): p. 39-54. 
20. Rettig W J, Erickson H P, Albino A P and Garin-Chesa P, Induction of human 
tenascin (neuronectin) by growth factors and cytokines: cell type-specific 
signals and signalling pathways. J Cell Sci, 1994. 107(2): p. 487-497. 
21. LaFleur D W, Fagin J A, Forrester J S, RubinO S A, et al., Cloning and 
Characterization of Alternatively Spliced Isoforms of Rat Tenascin: Platelet-
derived growth factor-BB markedly stimulates expression of spliced variants of 
tenascin mRNA in arterial smooth muscle cells. J Biol Chem, 1994. 269(32): p. 
20757-20763. 
22. Orend G and Chiquet-Ehrismann R, Tenascin-C induced signaling in cancer. 
Cancer Lett, 2006. 244(2): p. 143-163. 
23. Jinnin M, Ihn H, Asano Y, Yamane K, et al., Tenascin-C upregulation by 
transforming growth factor-in human dermal fibroblasts involves Smad3, Sp1, 
and Ets1. Oncogene, 2004. 23(9): p. 1656-1667. 
 References  
 
 
 103 
24. Ihida-Stansbury K, McKean D M, Lane K B, Loyd J E, et al., Tenascin-C is 
induced by mutated BMP type II receptors in familial forms of pulmonary 
arterial hypertension. Am J Physiol Lung Cell Mol Physiol, 2006. 291(4): p. 
694-702. 
25. Alford A I and Hankenson K D, Matricellular proteins: Extracellular modulators 
of bone development, remodeling, and regeneration. Bone, 2006. 38(6): p. 
749-757. 
26. Spinale F G, Myocardial matrix remodeling and the matrix metalloproteinases: 
influence on cardiac form and function. Physiol Rev, 2007. 87(4): p. 1285-
1342. 
27. Galoian K A, Garamszegi N, Garamszegi S P and Scully S P, Molecular 
mechanism of tenascin-C action on matrix metalloproteinase-1 invasive 
potential. Exp Biol Med, 2007. 232: p. 515-522. 
28. Siri A, Knäuper V, Veirana N, Caocci F, et al., Different susceptibility of small 
and large human tenascin-C isoforms to degradation by matrix 
metalloproteinases. J Biol Chem, 1995. 270(15): p. 8650-8654. 
29. Bell S C, Pringle J H, Taylor D J and Malak T M, Alternatively spliced 
tenascin-C mRNA isoforms in human fetal membranes. Mol Hum Reprod, 
1999. 5(11): p. 1066-1076. 
30. Jugdutt B I, Ventricular remodeling after infarction and the extracellular 
collagen matrix: When is enough enough? Circulation, 2003. 108(11): p. 1395-
1403. 
31. Joester A and Faissner A, The structure and function of tenascins in the 
nervous system. Matrix Biol, 2001. 20: p. 13-22. 
32. Bristow J, Tee M K, Gitelman S E, Mellon S H, et al., Tenascin-X: a novel 
extracellular matrix protein encoded by the human XB gene overlapping 
P450c21B. J Cell Biol, 1993. 122(1): p. 265-278. 
33. Burch G H, Gong Y, Liu W, Dettman R W, et al., Tenascin-X deficiency is 
associated with Ehlers-Danlos syndrome. Nat Genet, 1997. 17(1): p. 104-108. 
34. Matsumoto K, Saga Y, Ikemura T, Sakakura T, et al., The distribution of 
tenascin-X is distinct and often reciprocal to that of tenascin-C. J Cell Biol, 
1994. 125(2): p. 483-493. 
35. Chiquet-Ehrismann R and Chiquet M, Tenascins: regulation and putative 
functions during pathological stress. J Pathol, 2003. 200(4): p. 488-499. 
 References  
 
 
 104 
36. Bristow J, Carey W, Egging D and Schalkwijk J, Tenascin-X, collagen, elastin, 
and the Ehlers-Danlos syndrome. Am J Med Genet, 2005. 139(1): p. 24-30. 
37. Hagios C, Brown-Luedi M and Chiquet-Ehrismann R, Tenascin-Y, a 
component of distinctive connective tissues, supports muscle cell growth. Exp 
Cell Res, 1999. 253(2): p. 607-617. 
38. Hagios C, Koch M, Spring J, Chiquet M, et al., Tenascin-Y: a protein of novel 
domain structure is secreted by differentiated fibroblasts of muscle connective 
tissue. J Cell Biol, 1996. 134(6): p. 1499-1512. 
39. Weber P, Montag D, Schachner M and Bernhardt R R, Zebrafish tenascin-W, 
a new member of the tenascin family. J Neurobiol, 1998. 35(1): p. 1-16. 
40. Scherberich A, Tucker R P, Samandari E, Brown-Luedi M, et al., Murine 
tenascin-W: a novel mammalian tenascin expressed in kidney and at sites of 
bone and smooth muscle development. J Cell Sci, 2004. 117(4): p. 571-581. 
41. Siri A, Carnemolla B, Saginati M, Leprini A, et al., Human tenascin: primary 
structure, pre-mRNA splicing patterns and localization of the epitopes 
recognized by two monoclonal antibodies Nucleic Acids Res, 1991. 19(3): p. 
525-531. 
42. Oberhauser A F, Marszalek P E, Erickson H P and Fernandez J M, The 
molecular elasticity of the extracellular matrixprotein tenascin. Nature, 1998. 
393: p. 181-185. 
43. Kammerer R A, Schulthess T, Landwehr R, Lustig A, et al., Tenascin-C 
Hexabrachion Assembly Is a Sequential Two-step Process Initiated by Coiled-
coil -Helices. J Biol Chem, 1998. 273(17): p. 10602-10608. 
44. Jones P L and Jones F S, Tenascin-C in development and disease: gene 
regulation and cell function. Matrix Biol, 2000. 19(7): p. 581-596. 
45. Borsi L, Allemanni G, Gaggero B and Zardi L, Extracellular pH controls pre-
mRNA alternative splicing of tenascin-C in normal, but not in malignantly 
transformed, cells. Int J Cancer, 1998. 66(5): p. 632-635. 
46. Zhao Y and Young S L, TGF-beta regulates expression of tenascin 
alternative-splicing isoforms in fetal rat lung. Am J Physiol Lung Cell Mol 
Physiol, 1995. 268(2): p. 173-180. 
47. Joester A and Faissner A, Evidence for Combinatorial Variability of Tenascin-
C Isoforms and Developmental Regulation in the Mouse Central Nervous 
System. Biol Chem, 1999. 274(24): p. 17144-17151. 
 References  
 
 
 105 
48. Tucker R P, Hammarback J A, Jenrath D A, Mackie E J, et al., Tenascin 
expression in the mouse: in situ localization and induction in vitro by bFGF. J 
Cell Sci, 1993. 104(1): p. 69-76. 
49. Fischer D, Brown-Lüdi M, Schulthess T and Chiquet-Ehrismann R, Concerted 
action of tenascin-C domains in cell adhesion, anti-adhesion and promotion of 
neurite outgrowth. J Cell Sci, 1997. 110(13): p. 1513-1522. 
50. Prieto A L, Jones F S, Cunningham B A, Crossin K L, et al., Localization 
during development of alternatively spliced forms of cytotactin mRNA by in situ 
hybridization. J Cell Biol, 1990. 111(2): p. 685-698. 
51. Kaplony A, Zimmermann D R, Fischer R W, Imhof B A, et al., Tenascin Mr 
220,000 isoform expression correlates with corneal cell migration. 
Development, 1991. 112(2): p. 605-614. 
52. Borsi L, Carnemolla B, Nicolò G, Spina B, et al., Expression of different 
tenascin isoforms in normal, hyperplastic and neoplastic human breast 
tissues. Int J Cancer, 1992. 52(5): p. 688-692. 
53. Trebaul A, Chan E K and Midwood K S, Regulation of fibroblast migration by 
tenascin-C. Biochem Soc Trans, 2007. 35(4): p. 695-697. 
54. Bourdon M A and Ruoslahti E, Tenascin Mediates Cell Attachment through an 
RGD-dependent Receptor. J Cell Biol, 1989. 108: p. 1149-1155. 
55. Murphy-Ullrich J E, Lightner V A, Aukhil I, Yan Y Z, et al., Focal adhesion 
integrity is downregulated by the alternatively spliced domain of human 
tenascin. J Cell Biol, 1991. 115(4): p. 1127-1136. 
56. Chiquet-Ehrismann R, Matsuoka Y, Hofer U, Spring J, et al., Tenascin 
variants: differential binding to fibronectin and distinct distribution in cell 
cultures and tissues. Cell Regulation, 1991. 2: p. 927-938. 
57. Huang W, Chiquet-Ehrismann R, Moyano J V, Garcia-Pardo A, et al., 
Interference of tenascin-C with syndecan-4 binding to fibronectin blocks cell 
adhesion and stimulates tumor cell proliferation. Cancer Res, 2001. 61: p. 
8586-8594. 
58. Götz B, Scholze A, Clement A, Joester A, et al., Tenascin-C contains distinct 
adhesive, anti-adhesive, and neurite outgrowth promoting sites for neurons J 
Cell Biol, 1996. 132(4): p. 681-699. 
 References  
 
 
 106 
59. Wallner K, Shah P K  and Sharifi B G, Balloon catheterization induces arterial 
expression of new Tenascin-C isoform. Atherosclerosis, 2002. 161(1): p. 75-
83. 
60. Sriramarao P and Bourdon M A, A novel tenascin type III repeat is part of a 
complex of tenascin mRNA alternative splices. Nucleic Acids Res, 1993. 
21(1): p. 163-168. 
61. Mighell A J, Thompson J, Hume W J, Markham A F, et al., Human tenascin-C: 
identification of a novel type III repeat in oral cancer and of novel splice 
variants in normal, malignant and reactive oral mucosae. Int J Cancer, 1997. 
72(2): p. 236-240. 
62. Tucker R P, Spring J, Baumgartner S, Martin D, et al., Novel tenascin variants 
with a distinctive pattern of expression in the avian embryo. Development, 
1994. 120(3): p. 637-647. 
63. Hanamura N, Yoshida T, Matsumoto E, Kawarada Y, et al., Expression of 
fibronectin and tenascin-C mRNA by myofibroblasts, vascular cells and 
epithelial cells in human colon adenomas and carcinomas. Int J Cancer, 1997. 
73(1): p. 10-15. 
64. Berndt A, Anger K, Richter P, Borsi L, et al., Differential expression of 
tenascin-C splicing domains in urothelial carcinomas of the urinary bladder. J 
Cancer Res Clin Oncol, 2006. 132(8): p. 537-546. 
65. Franz M, Hansen T, Borsi L, Geier C, et al., A quantitative co-localization 
analysis of large unspliced tenascin-CL and laminin-5/c2-chain in basement 
membranes of oral squamous cell carcinoma by confocal laser scanning 
microscopy. J Oral Pathol Med, 2007. 36(1): p. 6-11. 
66. Dueck M, Riedl S, Hinz U, Tandara A, et al., Detection of tenascin-C isoforms 
in colorectal mucosa, ulcerative colitis, carcinomas and liver metastases. Int J 
Cancer, 1999. 82(4): p. 477-483. 
67. Willems I E, Arends J W and Daemen M J, Tenascin and fibronectin 
expression in healing human myocardial scars. J Pathol, 1996. 179(3): p. 321-
325. 
68. Mackie E J, Halfter W and Liverani D, Induction of tenascin in healing wounds. 
J Cell Biol, 1988. 107(6): p. 2757-2767. 
 References  
 
 
 107 
69. Latijnhouwers M A, de Jongh G J, Bergers M, de Rooij M J, et al., Expression 
of tenascin-C splice variants by human skin cells. Arch Dermatol Res, 2000. 
292(9): p. 446-454. 
70. Filenius S, Tervo T and Virtanen I, Production of fibronectin and tenascin 
isoforms and their role in the adhesion of human immortalized corneal 
epithelial cells. Invest Ophthalmol Vis Sci, 2003. 44(8): p. 3317-3325. 
71. Thygesen K, Alpert J S and White H D, Universal definition of myocardial 
infarction. Circulation, 2007. 116(22): p. 2634-2653. 
72. Anand S S, Islam S, Rosengren A, Franzosi M G, et al., Risk factors for 
myocardial infarction in women and men: insights from the INTERHEART 
study. Eur Heart J, 2008. 29(7): p. 932-940. 
73. Goldthwaite C A, Mending a broken heart: stem cells and cardiac repair. 
Regenerative Medicine, 2006(6). 
74. Dobaczewski M, Bujak M, Zymek P, Ren G, et al., Extracellular matrix 
remodeling in canine and mouse myocardial infarcts. Cell Tissue Res, 2006. 
324(3): p. 475-488. 
75. Morrow D A and de Lemos J A, Benchmarks for the assessment of novel 
cardiovascular biomarkers. Circulation, 2007. 115(8): p. 949-952. 
76. Adams III J E, Clinical application of markers of cardiac injury: basic concepts 
and new considerations. Clin Chimica, 1999. 284: p. 127-134. 
77. Karras D J and Kane D L, Serum markers in the emergency department 
diagnosis of acute myocardial infarction. Emerg Med Clin North Am, 2001. 
19(2): p. 321-337. 
78. Jaffe A S, Babuin L and Apple F S, Biomarkers in acute cardiac disease. J Am 
Coll Cardiol, 2006. 48(1): p. 1-11. 
79. Braunwald E, Biomarkers in heart failure. N Engl J Med, 2008. 358(20): p. 
2148-2159. 
80. Mueller C, Mueller B and Perruchoud A P, Biomarkers: past, present, and 
future. Swiss Med WKLY, 2008. 138(15-16): p. 225-229. 
81. Alpert J S, Malasky B R and Thygesen K, Redefining myocardial infarction for 
the 21st century. Trans Am Clin Climatol Assoc, 2004. 115: p. 79-94. 
82. Warburton F G, Allan E, Laing G S and Waddecar J, Increased Lactate 
Dehydrogenase 3 in Serum after Myocardial Infarction. Nature, 1967. 215: p. 
287-289. 
 References  
 
 
 108 
83. Sato I and Shimada K, Quantitative analysis of tenascin in chordae tendineae 
of human left ventricular papillary muscle with aging. Ann Anat, 2001. 183(5): 
p. 443-448. 
84. Imanaka-Yoshida K, Hiroe M, Yasutomi Y, Toyozaki T, et al., Tenascin-C is a 
useful marker for disease activity in myocarditis. J Pathol, 2002. 197(3): p. 
388-394. 
85. Imanaka-Yoshida K, Hiroe M, Nishikawa T, Ishiyama S, et al., Tenascin-C 
modulates adhesion of cardiomyocytes to extracellular matrix during tissue 
remodeling after myocardial infarction. Lab Invest, 2001. 81(7): p. 1015-1024. 
86. Imanaka-Yoshida K, Knudsen K A and Linask K K, N-cadherin is required for 
the differentiation and initial myofibrillogenesis of chick cardiomyocytes. Cell 
Motil Cytoskeleton, 1998. 39(1): p. 52-62. 
87. Linask K K and Lash J W, Early heart development: dynamics of endocardial 
cell sorting suggests a common origin with cardiomyocytes. Dev Dyn, 1993. 
196(1): p. 62-69. 
88. Imanaka-Yoshida K, Matsumoto K, Hara M, Sakakura T, et al., The dynamic 
expression of tenascin-C and tenascin-X during early heart development in the 
mouse. Differentiation, 2003. 71(4-5): p. 291-298. 
89. Tremble P, Chiquet-Ehrismann R and Werb Z, The extracellular matrix ligands 
fibronectin and tenascin collaborate in regulating collagenase gene expression 
in fibroblasts. Mol Biol Cell, 1994. 5: p. 439-453. 
90. Ducharme A, Frantz S, Aikawa M, Rabkin E, et al., Targeted deletion of matrix 
metalloproteinase-9 attenuates left ventricular enlargement and collagen 
accumulation after experimental myocardial infarction. J Clin Invest, 2000. 
106(1): p. 55-62. 
91. Sato A, Aonuma K, Imanaka-Yoshida K, Yoshida T, et al., Serum tenascin-C 
might be a novel predictor of left ventricular remodeling and prognosis after 
acute myocardial infarction. J Am Coll Cardiol, 2006. 47(11): p. 2319-2325. 
92. Tamaoki M, Imanaka-Yoshida K, Yokoyama K, Nishioka T, et al., Tenascin-C 
regulates recruitment of myofibroblasts during tissue repair after myocardial 
injury. Am J Pathol, 2005. 167(1): p. 71-78. 
93. Saga Y, Yagi T, Ikawa Y, Sakakura T, et al., Mice develop normally without 
tenascin. Genes Dev, 1992. 6(10): p. 1821-1831. 
 References  
 
 
 109 
94. Morimoto S, Imanaka-Yoshida K, Hiramitsu S, Kato S, et al., Diagnostic utility 
of tenascin-C for evaluation of the activity of human acute myocarditis. J 
Pathol, 2005. 205(4): p. 460-467. 
95. Frangogiannis N G, Shimoni S, Chang S M, Ren G, et al., Active interstitial 
remodeling: An important process in the hibernating human myocardium. J 
Am Coll Cardiol, 2002. 39(9): p. 1468-1474. 
96. Tamura A, Kusachi S, Nogami K, Yamanishi A, et al., Tenascin expression in 
endomyocardial biopsy specimens in patients with dilated cardiomyopathy: 
distribution along margin of fibrotic lesions. Heart, 1996. 75(3): p. 291-294. 
97. Aso N, Tamura A and Nasu M, Circulating tenascin-C levels in patients with 
idiopathic dilated cardiomyopathy. Am J Cardiol, 2004. 94(11): p. 1468-1470. 
98. Terasaki F, Okamoto H, Onishi K, Sato A, et al., Higher serum tenascin-C 
levels reflect the severity of heart failure, left ventricular dysfunction and 
remodeling in patients with dilated cardiomyopathy. Circ J, 2007. 71: p. 327-
330. 
99. Chiquet-Ehrismann R, Molecules in focus - Tenascins. Int J Biochem & Cell 
Biol, 2004. 36(6): p. 986-990. 
100. Brack S S, Silacci M, Birchler M and Neri D, Tumor-targeting properties of 
novel antibodies specific to the large isoform of tenascin-C. Clin Cancer Res, 
2006. 12(10): p. 3200-3208. 
101. Reardon D A, Akabani G, Coleman R E, Friedman A H, et al., Phase II trial of 
murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered 
into surgically created resection cavities of patients with newly diagnosed 
malignant gliomas. J Clin Oncol, 2002. 20(5): p. 1389-1397. 
102. Brown M T, Coleman R E, Friedman A H, Friedman H S, et al., Intrathecal 
131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with 
leptomeningeal neoplasms or primary brain tumor resection cavities with 
subarachnoid communication: phase I trial results. Clin Cancer Res, 1996. 
2(6): p. 963-972. 
103. Bigner D D, Brown M, Coleman E R, Friedman A H, et al., Phase I studies of 
treatment of malignant gliomas and neoplastic meningitis with131I-
radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin 
proteoglycan sulfate Me1-14 F (ab′) 2-a preliminary report. J Neuro Oncol, 
1995. 24(1). 
 References  
 
 
 110 
104. Hicke B J, Marion C, Chang Y F, Gould T, et al., Tenascin-C aptamers are 
generated using tumor cells and purified protein. J Biol Chem, 2001. 276(52): 
p. 48644-48654. 
105. Hasegawa M, Nakoshi Y, Muraki M, Sudo A, et al., Expression of large 
tenascin-C splice variants in synovial fluid of patients with rheumatoid arthritis. 
J Orthop Res, 2007. 25(5): p. 563-568. 
106. Riedl S, Tandara A, Reinshagen M, Hinz U, et al., Serum tenascin-C is an 
indicator of inflammatory bowel disease activity. Int J Colorectal Dis, 2001. 
16(5): p. 285-291. 
107. Tanaka H, El-Karef A, Kaito M, Kinoshita N, et al., Circulating level of large 
splice variants of tenascin-C is a marker of piecemeal necrosis activity in 
patients with chronic hepatitis C. Liver Int, 2006. 26(3): p. 311-318. 
108. Spinale F G, Coker M L, Bond B R and Zellner J L, Myocardial matrix 
degradation and metalloproteinase activation in the failing heart: a potential 
therapeutic target. Cardiovasc Res, 2000. 46: p. 225-238. 
109. Pfeffer M A, Pfeffer J M, Fishbein M C, Fletcher P J, et al., Myocardial infarct 
size and ventricular function in rats. Circ Res, 1979. 44(4): p. 503-512. 
110. Podesser B K, Schirnhofer J, Bernecker O Y, Kroner A, et al., Optimizing 
ischemia/reperfusion in the failing rat heart--improved myocardial protection 
with acute ACE inhibition. Circulation, 2002. 106(12 Suppl 1): p. I277-I283. 
111. Trescher K, Bernecker O, Fellner B, Gyongyosi M, et al., Inflammation and 
postinfarct remodeling: overexpression of IkappaB prevents ventricular dilation 
via increasing TIMP levels. Cardiovasc Res, 2006. 69(3): p. 746-754. 
112. Klocke R, Tian W, Kuhlmann M T and Nikol S, Surgical animal models of heart 
failure related to coronary heart disease. Cardiovasc Res, 2006. 74(1): p. 29-
38. 
113. DATAPHARM Netsystems GMBH, http://www.kardionet.de. 
114. Aukhil I, Rattus norvegicus tenascin-C mRNA, partial cds, 1856 bp mRNA 
(U15550.1) GenBank: U15550.1, 1994. 
115. Thometich B, Schmidt W M, Bittner R E and Podesser B K, Rattus norvegicus 
tenascin C (Tnc) mRNA, complete cds, 6155 bp mRNA. GenBank: 
EU596506.1, 2008. 
 References  
 
 
 111 
116. Nies D E, Hemesath T J, Kim J H, Gulcher J R, et al., The Complete cDNA 
Sequence of Human Hexabrachion (Tenascin). J Biol Chem, 1991. 266(5): p. 
2818-2823. 
117. Weller A, Beck S and Ekblom P, Amino acid sequence of mouse tenascin and 
differential expression of two tenascin isoforms during embryogenesis. J Cell 
Biol, 1988. 107: p. 2341-2349. 
118. Matsumoto K, Hiraiwa N, Yoshiki A, Ohnishi M, et al., Tenascin-C expression 
and splice variant in habu snake venom-induced glomerulonephritis. Exp Mol 
Pathol, 2002. 72(3): p. 186-195. 
119. Adams M, Jones J L, Walker R A, Pringle J H, et al., Changes in tenascin-C 
isoform expression in invasive and preinvasive breast disease. Cancer Res, 
2002. 62(11): p. 3289-3297. 
120. Chiquet-Ehrismann R, What distinguishes tenascin from fibronectin? FASEB 
J, 1990. 4(9): p. 2598-2604. 
121. Ljubimov A V, Saghizadeh M, Spirin K S, Khin H L, et al., Expression of 
tenascin-C splice variants in normal and bullous keratopathy human corneas. 
Invest Ophthalmol Vis Sci, 1998. 39(7): p. 1135-1142. 
122. Dang C, Gottschling M, Roewert J, Forschner T, et al., Tenascin-C patterns 
and splice variants in actinic keratosis and cutaneous squamous cell 
carcinoma. Br J Dermatol, 2006. 155(4): p. 763-770. 
123. Takeda A, Otani Y, Iseki H, Takeuchi H, et al., Clinical significance of large 
tenascin-C spliced variant as a potential biomarker for colorectal cancer. 
World J Surg, 2007. 31(2): p. 388-394. 
124. Frangogiannis N G, The mechanistic basis of infarct healing. Antioxid Redox 
Signal, 2006. 8(11-12): p. 1907-1939. 
125. Weisman H F, Bush D E, Mannisi J A, Weisfeldt M L, et al., Cellular 
Mechanisms of Myocardial Infarct Expansion. Circulation, 1988. 78(1): p. 186-
201. 
126. Dobaczewski M, Gonzalez-Quesada C and Frangogiannis N G, The 
extracellular matrix as a modulator of the inflammatory and reparative 
response following myocardial infarction. J Mol Cell Cardiol, 2009. 
127. Whittaker P, Boughner D R and Kloner R A, Role of collagen in acute 
myocardial infarct expansion. Circulation, 1991. 84(5): p. 2123-2134. 
 References  
 
 
 112 
128. El-Karef A, Kaito M, Tanaka H, Ikeda K, et al., Expression of large tenascin-C 
splice variants by hepatic stellate cells/myofibroblasts in chronic hepatitis C. J 
Hepatol, 2007. 46(4): p. 664-673. 
129. Zhao Y, Young S L and McIntosh J C, Induction of tenascin in rat lungs 
undergoing bleomycin-induced pulmonary fibrosis. Am J Physiol, 1998. 274(6 
Pt 1): p. 1049-1057. 
130. Liakka K A and Autio-Harmainen H I, Distribution of the extracellular matrix 
proteins tenascin, fibronectin, and vitronectin in fetal, infant, and adult human 
spleens. J Histochem Cytochem, 1992. 40(8): p. 1203-1210. 
131. Aufderheide E, Chiquet-Ehrismann R and Ekblom P, Epithelial-mesenchymal 
interactions in the developing kidney lead to expression of tenascin in the 
mesenchyme. J Cell Biol, 1987. 105(1): p. 599-608. 
132. Weber P, Bartsch U, Rasband M N, Czaniera R, et al., Mice deficient for 
tenascin-R display alterations of the extracellular matrix and decreased axonal 
conduction velocities in the CNS. J Neurosci, 1999. 19(11): p. 4245-4262. 
133. Matsumoto K, Takayama N, Ohnishi J, Ohnishi E, et al., Tumour invasion and 
metastasis are promoted in mice deficient in tenascin-X. Genes Cells, 2001. 
6(12): p. 1101-1111. 
134. Matsumoto K, Takahashi K, Yoshiki A, Kusakabe M, et al., Invasion of 
melanoma in double knockout mice lacking tenascin-X and tenascin-C. Jpn J 
Cancer Res, 2002. 93(9): p. 968-975. 
135. Guntinas-Lichius O, Angelov D N, Morellini F, Lenzen M, et al., Opposite 
impacts of tenascin-C and tenascin-R deficiency in mice on the functional 
outcome of facial nerve repair. J Neurosci, 2005. 22: p. 2171-2179. 
136. Mackie E J and Tucker R P, The tenascin-C knockout revisited. J Cell Sci, 
1999. 112(Pt 22): p. 3847-3853. 
137. Fukamauchi F, Mataga N, Wang Y J, Sato S, et al., Abnormal behavior and 
neurotransmissions of tenascin gene knockout mouse. Biochem & Biophys 
Res Communications, 1996. 221(1): p. 151-156. 
138. Forsberg E, Hirsch E, Fröhlich L, Meyer M, et al., Skin wounds and severed 
nerves heal normally in mice lacking tenascin-C. Medical Sci, 1996. 93(13): p. 
6594-6599. 
 References  
 
 
 113 
139. Trueblood N A, Xie Z, Communal C, Sam F, et al., Exaggerated left ventricular 
dilation and reduced collagen deposition after myocardial infarction in mice 
lacking osteopontin. Circ Res, 2001. 88(10): p. 1080-1087. 
140. Blankesteijn W M, Creemers E, Lutgens E, Cleutjens J P, et al., Dynamics of 
cardiac wound healing following myocardial infarction: observations in 
genetically altered mice. Acta Physiol Scand, 2001. 173(1): p. 75-82. 
141. Mao J R and Bristow J, The Ehlers-Danlos syndrome: on beyond collagens. J 
Clin Invest, 2001. 107(9): p. 1063-1069. 
142. Milting H, Ellinghaus P, Seewald M, Cakar H, et al., Plasma biomarkers of 
myocardial fibrosis and remodeling in terminal heart failure patients supported 
by mechanical circulatory support devices. J Heart Lung Transplant, 2008. 27: 
p. 589-596. 
143. Reardon D A, Zalutsky M R, Akabani G, Coleman R E, et al., A pilot study: 
131I-Antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection 
cavity boost. Neuro Oncol, 2008. 10(2): p. 182-189. 
144. Zalutsky M R, Reardon D A, Akabani G, Coleman R E, et al., Clinical 
experience with alpha-particle emitting 211At: treatment of recurrent brain 
tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 
81C6. J Nucl Med, 2008. 49(1): p. 30-38. 
 
 
 
____________________________________________________________________ 
 
 114 
       Abbreviations     
 
 
 115 
7. ABBREVIATIONS 
 
 
AD1+2: additional domain 1+2 
AK: actinic keratosis 
AMI: acute myocardial infarction 
APS: Ammonium persulfate 
ASMC: aortic smooth muscle cells  
BCP: 1-bromo-3-chloro-propane 
bFGF: basic fibroblast growth factor 
BNP: brain natriuretic peptide 
CHC: chronic hepatitis C 
CK: creatin kinase 
CNS: central nervous system 
CRP: C-reactive protein 
CTGF: connective tissue growth factor 
CV: coefficient of variation 
DAB: diaminobenzidine 
DCIS: ductal carcinoma in situ 
DCM: dilated cardiomyopathy  
DMD/BMD: Duchenne/Becker muscular dystrophy 
DMSO: dimethyl sulfoxide  
dNTP: deoxyribonucleotide triphosphate 
E: embryonic day 
ECL: enhanced-chemiluminescence  
ECM: extra cellular matrix 
EDS: Ehler-Danlos Syndrome 
EDTA: ethylene diamine tetraacetic acid 
EF: ejection fraction 
EGF: epidermal growth factor 
EGF-L repeats: epidermal growth factor like repeats  
EGTA: ethylene glycol tetra acetic acid  
ELISA: enzyme-linked immunosorbent assays 
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EtOH: ethanol 
FG: fibrinogen globe 
FN: fibronectin 
FN-III domains:  fibronectin type III domains  
For: forward 
GAPDH: glyceraldehyde 3-phosphate dehydrogenase 
GMEM: glial/mesenchymal extracellular matrix protein 
H: hour 
HCE: human corneal epithelial cells  
HDL: high density lipoprotein 
H&E staining: hematoxylin and eosin staining 
HRP: horse radish peroxidase 
HSCs: hepatic stellate cells 
HSV: habu snake venom 
IBD: inflammatory bowel disease 
IDC: idiopathic dilated cardiomyopathy 
IFN-γ: interferon γ 
IHC staining: immunohistochemical staining 
IL: interleukin 
i.p.: intraperitoneal 
i.m.: intramuscular 
kDa: kilodalton  
L: liter  
LAD: left anterior descending coronary artery 
LDH: lactate dehydrogenase 
LDL: low density lipoprotein 
LEF: lymphoid enhancer-binding factor 
LV: left ventricle 
MAb: monoclonal antibody 
MACE: major adverse cardiac events 
MAPK pathway: mitogen-activated protein kinase pathway 
MHC: major histocompatibility complex  
MI: myocardial infarction 
Min: minutes 
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MMP: matrix metalloproteinases 
NBT: nitro blue tetrazolium 
NfκB: nuclear factor kappa-light-chain-enhancer of activated B cells 
NT-proBNP: amino terminal fragment of proBNP 
Ns: not significant 
NYHA: New York Heart Association 
OMI: old myocardial infarction 
OPC: oligodendrocyte precursor cells  
OPN: osteopontin 
OSCC: oral squamous cell carcinoma 
P6: postnatal day 6 
PBS: phosphate buffered saline 
PCR: polymerase chain reaction 
PDGF: platelet-derived growth factor 
PEO: pro-epicardial organ  
PVDF: polyvinylidenfluorid 
RAAS: renin-angiotensin-aldosterone system 
Ras protein: rat sarcoma protein 
Rev: reverse 
RGD motive: contains amino acids: R = arginine, G = glycine and D = asparagine 
RNA: Ribonucleic acid 
ROS: reactive oxygen species 
RT: room temperature 
SCC: squamous cell carcinoma 
SD: standard deviation 
SDS: sodium dodecyl sulfate 
SGOT: serum glutamate oxaloacetate transaminase 
SMC: smooth muscle cells  
SPARC: osteonectin (also known as BM-40) 
SPX domain: serine-proline rich domain 
TA domain: tenascin assembly domain 
TBS: tris buffered saline 
TBS-T: tris buffered saline with tween 
TCF: T cell-specific transcription factor 
       Abbreviations     
 
 
 118 
TEMED: tetramethylethylenediamine 
TGF-β: transforming growth factor β 
TGF: transforming growth factor 
TIMP: tissue inhibitors of matrix metalloproteinases 
TN: tenascin 
TN-CL: large tenascin-C isoform 
TN-CS: small tenascin-C isoform 
TNF-α: tumour necrosis factor α 
TSP1: thrombospondin-1 
TSP2: thrombospondin-2 
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8. APPENDIX 
 
 
8.1. Rat TN-C: cDNA Sequence 
 
Rattus norvegicus tenascin-C (TN-C) mRNA, complete cds (GenBank, EU596506) 
 
   1 ccctacagat ctagagacac ctagccaatc caacctctac catgggggcc gtgrcctggc 
  61 tattgccagg catcttccta gctttgtttg ccctcactcc tgaaggtggg gtcctcaaga 
 121 aagtcatcag gcacaagcga gagagtgggc tgaacttgac cttgccagag gagaatcagc 
 181 cagtggtgtt caaccatgtc tacaacatca agttgcccat gggttctcag tgctcagtgg 
 241 atctagagtc aacgagtgga gagaaagacc tgagccccac accagagtcc agtggaagct 
 301 tccaggagca tacagtggat ggggaaaatc agattgtgtt cacacaccgc atcaacatcc 
 361 ctcgtcgggc ctgtggctgt gccgcagctc cagatgtgaa ggagctcctg agcagactgg 
 421 aggaactgga gatgttggta tcttctctaa gggagcagtg caccatgggt acaggctgtt 
 481 gcctccaacc tgcagaaggc cgtctggaca gcaggccctt ctgcagcggc aggggtaact 
 541 tcagtgctga aggttgtggc tgtgtctgtg aaccaggctg gaaaggtccc aactgctctg 
 601 agcctgaatg ccctggaaac tgtaatctca gaggccagtg ccttgatgga cagtgtatct 
 661 gtgaccaggg tttcactggg gaagactgca gccagctagc ctgtcccaat gactgcaatg 
 721 accagggcaa gtgtgtgaat ggggtctgtg tgtgcttcga aggctatgcc ggccttgact 
 781 gtggcctgga agtctgccca gtgccgtgca gcgaggaaca cgggatgtgt gtggatggca 
 841 ggtgtgtgtg caaagatggc tttgctggtg aagactgcaa tgagcccctt tgcttcaaca 
 901 actgcaacaa ccgtgggcgg tgtgtggaga acgaatgcgt ctgtgatgag ggcttcacgg 
 961 gcgaagactg cagcgagctc atttgcccca atgactgctt cgaccgaggt cgctgcatca 
1021 acggcacctg ctactgtgaa gaaggtttca caggtgaaga ctgtggtgag ctcacctgcc 
1081 ccaacaactg tcagggccat ggccagtgtg aagagggaca gtgtgtttgc aacgagggct 
1141 ttgcaggggc agactgcagt gaaaagcggt gtcccgcaga ctgtcaccac catggccgct 
1201 gtctcaacgg acagtgtgag tgtgacgatg ggttcacagg ggctgactgt ggggaactcc 
1261 agtgccccaa tggctgcagt gggcatggcc gctgtgtcaa tgggcagtgt gtgtgtgacg 
1321 agggctacac cggagaagac tgtagccaac ggcgatgccc caatgactgc cacaaccggg 
1381 gtcactgtgt acagggcaaa tgcatatgtg agcaaggctt caaaggcttt gactgtagtg 
1441 agatgagctg tcccaatgac tgccaccagc atggccgctg tgtgaatggc atgtgcatct 
1501 gtgatgatga ctacactggg gaagactgca gagaccgccg ctgtccccgg gactgtagcc 
1561 agcgggggcg ctgtgtggac ggacagtgca tttgtgagga tggtttcact ggttctgact 
1621 gtgctgagct ctcctgccct ggtgactgcc acggccatgg ccgctgtgtg aatggccaat 
1681 gcatctgcca cgagggcttc accggcraag actgcaaaga gcaaaggtgc cccagtgact 
1741 gccatggcca aggccgctgt gaggacggcc aatgtatctg ccatgagggc ttcacaggcc 
1801 tggactgtgg gcagcgctcc tgtcccaatg actgcagcaa ccagggacaa tgtgtggcag 
1861 gccgctgcat ctgcaatgaa ggctacacag gggtagactg ctctgaggtg tcccctccca 
1921 aagaccttat tgtgacagaa gtaacagagg agactgtara tctggcatgg gacaatgaga 
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1981 tgcgggtcac tgagtacctc attatgtaca cacccaccca tgctgatggc ctggagatgc 
2041 agttccgtgt gcctggggac cagacatcta ccaccatccg ggagctggag ccaggagtgg 
2101 agtacttcat tcgtgtgttc gccatcttgg agaacaagag gagcatccct gtcagtgcca 
2161 gagttgccac ctacttgcct gcacctgaag gcctaaaatt caagtctatc aaggagacat 
2221 ctgtggaagt agagtgggat cctctggaca tcgcttttga aacgtgggag atcattttca 
2281 gaaatatgaa caaagaagat gagggagaga tcacaaaaag cttgaggagg ccagagacct 
2341 cctaccgcca aactggcctg gctcctggcc aagaatatga aatatctctt cacattgtga 
2401 aaaacaacac ccgaggccct ggcttgaaga aagtgaccac aactcgcctg gatgccccca 
2461 gccaaattga ggtgagagac atcacagaca ctacagcact gatcacctgg tccaagccct 
2521 tggctgaaat tgatagcatt gagctctcct atggcatcaa ggatgtgcct ggagaccgga 
2581 ccaccatcga cctcacacat gaagacaacc agtactccat cgggaacctg aaacctgaca 
2641 cggagtatga ggtgtccctc atctcccgca gagtggacat ggcaagcaac cctgccaagg 
2701 agaccttcat cacaggcctg gatgctccca ggaatctccg tcgcgtctca cagacagaca 
2761 acagcatcac cttggagtgg aggaatgtca aggcagacat tgatagttat agaattaagt 
2821 atgcacctat ctctggaggt gaccatgctg agatagatgt tccaaagagc cagcaagcca 
2881 caaccaaaac cacactcaca ggtctaaggc caggaactga atatggagtg ggcgtctctg 
2941 ctgttaaggg agacaaggag ggcgatccag caaccatcaa tgcagccaca gaaattgatg 
3001 cacccaggga cttacaggtg tctgagacca cacaagacag tctgacttta ttctggaaga 
3061 cacctctggc caagtttgat cgttaccgcc tcaactacag cctccccaca ggccagtcaa 
3121 tagagattca gctgccaaag gatgccacct cccatgtcct gacagacctg gagccagggc 
3181 aagaatacac tgttctcctc accgctgaga agggcagaca taagagcaag cctgcgcgtg 
3241 tgaaggcatc cacagaagaa gtaccttctc tggaaaatct caccgtgact gaggccggct 
3301 gggatggcct cagactcaac tggactgcag atgacctggc ctatgagtac tttgttattc 
3361 aggtacagga agccaacaag gtggagactg ctcacaactt cacagtactt ggtaacctcc 
3421 ggactgcaga catcccgggc ctcaaggctg ccactcctta tagagtctcc atttatgggg 
3481 tagctcgggg ctataaaaca cccgtgctct ctgctgagac cttcacaggg aaaactccca 
3541 gtttgggaga ggtgactgtg gctgaggtgg gctgggatgc cctcaagctc aactggactg 
3601 ctccagaagg agcctatacg aactttttca ttcaggtgct agaggctgac atgacccaga 
3661 ctgtccagaa cctcacagtc ccagggggac tgaggtcagt ggacctacct gggctcaaag 
3721 cagccacccg ctattacatc accgttcgag gggtcaccca ggacttcagc acagcccctc 
3781 tctctgttga ggtcttgaca gaggagatcc ctcaactggg aggcttgtcc gtgactgagg 
3841 tcagctggga cagccttaca ctcaactgga ccacagatga tctggcctat aagcacttta 
3901 tcattcaggt gcaggaggcc aacaatgtag aggctgctca gaacctcaca gtatctggta 
3961 gcctcagagt tgtggacatc ccaggcctca aggctgatac cccttataga gtctccatct 
4021 atggggtgat ccagggctat agaacaccaa tgctctctgc tgatgtctcc acagccaaag 
4081 aacctgaaat tggaaactta aatatttctg atgtaactcc tgagagcttc aatctctcct 
4141 ggacagctac cgacgggatc ttcgacatgt ttactatcga aattattgat tctaataggt 
4201 tgctgcagac agcagaacat aatatatctg gtgctgaacg aactgcccac atctcgggcc 
4261 ttccacctag tactgatttc attgtctacc tctctggaat tgctcccagc atccgtacca 
4321 aaaccatcag taccacagcc accacagaag ctgaaccgga agttgacaac cttctagttt 
4381 cagatgctac tccagacggt ttctgtctgt cctggactgc tgatgaaggg atattcgaca 
4441 gttttgttat caggatcaga gataccaaaa agcaatctga accacaagaa ataaccctcc 
4501 cttcccccga ccgtaccagg gacataacag gtctcagaga ggccactgag tacgaaattg 
       Appendix    
 
 
 121 
4561 aactctatgg aataagccgt ggaaggcgat cccagccagt cagtgccata gcaacaacag 
4621 ccatgggctc tccgaaggaa atcatgttct cagacatcac tgaaaatgca gccacagtca 
4681 gctggagggc accgactgct caggtggaga gtttccggat tacttatgtg cctgtaacag 
4741 gaggtccccc atccatggtg accgtggatg ggacggatac tgagacccga ctggtgaggc 
4801 tcacccctgg agtggagtac cacgtcagtg tgattgccat gaagggattt gaagaaagtg 
4861 atccggtctc ggggtctcta atcacagctc tcgatggtcc atctggcctt ctgacagcca 
4921 acatcacaga ctcagaagcc ttggccatgt ggcagccggc cattgccact gtggacagtt 
4981 atgtcatctc ctacacaggg gagagagtgc cagaaattac ccgcacagtg tctgggaata 
5041 cagtggagtt tgaactacat gacctggagc ctgccacaga gtacacactg agtgtctttg 
5101 cagagaaagg tcaccagaag agttctacca tcgctacgaa atttaccaca gacctggatt 
5161 ccccaagaga attgactgct actgaggttc agtcagaaac tgccttcctc acctggagac 
5221 ctccccgggc atcggtcact ggatacctcc tggtctatga gtctgtggat ggtacagtca 
5281 aggaagtcat tgtggggcct gacaccacct cctacagcct ggcagacctg agcccatcca 
5341 cccactacac agcaagaatc caggcattga gtgggtccct gaggagcaaa ctgatccaaa 
5401 ccatcttcac cacaattgga ctcctatatc cattccctag ggattgctct caagcaatgt 
5461 tgaatggcga caccacctct ggcctctata ccatctatat aaatggtgac aagactcaag 
5521 cactggaagt ctactgtgat atgacctctg atggaggtgg atggatcgtt ttcctgagac 
5581 gcaaaaatgg acgtgaggac ttctatcgaa actggaaggc ctatgccact gggtttggag 
5641 accgcagaga agaattctgg cttggactgg ataacctgag caaaatcaca gcccaagggc 
5701 aatatgagct ccgggtggac ctacaagacc atggggagtc agcctatgct gtgtatgaca 
5761 ggttcagtgt tggagatgcc aagagtcgct acaagctgaa ggtagaagga tacagtggaa 
5821 cggcaggtga ctccatgaac tatcacaatg gtagatcctt ctctacctat gacaaggaca 
5881 cagactcagc catcaccaac tgtgccctgt cctacaaagg agctttctgg tataagaact 
5941 gtcatcgtgt caacctgatg ggcagatatg gggacaataa tcacagtcag ggtgttaact 
6001 ggttccactg gaagggccat gagtactcaa tccagtttgc ggagatgaaa ctaagaccca 
6061 gcaacttccg aaatctggaa ggcaggcgta agcgggcata aatcccaggg acaatttggt 
6121 gagagaggaa tggggcccag agaaaacagg atttt 
 
 
8.2. Rat TN-C: Translation 
 
MGAVXWLLPGIFLALFALTPEGGVLKKVIRHKRESGLNLTLPEE     
NQPVVFNHVYNIKLPMGSQCSVDLESTSGEKDLSPTPESSGSFQEHTVDGENQIVFTH 
RINIPRRACGCAAAPDVKELLSRLEELEMLVSSLREQCTMGTGCCLQPAEGRLDSRPF 
CSGRGNFSAEGCGCVCEPGWKGPNCSEPECPGNCNLRGQCLDGQCICDQGFTGEDCSQ 
LACPNDCNDQGKCVNGVCVCFEGYAGLDCGLEVCPVPCSEEHGMCVDGRCVCKDGFAG 
EDCNEPLCFNNCNNRGRCVENECVCDEGFTGEDCSELICPNDCFDRGRCINGTCYCEE 
GFTGEDCGELTCPNNCQGHGQCEEGQCVCNEGFAGADCSEKRCPADCHHHGRCLNGQC 
ECDDGFTGADCGELQCPNGCSGHGRCVNGQCVCDEGYTGEDCSQRRCPNDCHNRGHCV 
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QGKCICEQGFKGFDCSEMSCPNDCHQHGRCVNGMCICDDDYTGEDCRDRRCPRDCSQR 
GRCVDGQCICEDGFTGSDCAELSCPGDCHGHGRCVNGQCICHEGFTGXDCKEQRCPSD 
CHGQGRCEDGQCICHEGFTGLDCGQRSCPNDCSNQGQCVAGRCICNEGYTGVDCSEVS 
PPKDLIVTEVTEETVBLAWDNEMRVTEYLIMYTPTHADGLEMQFRVPGDQTSTTIREL 
EPGVEYFIRVFAILENKRSIPVSARVATYLPAPEGLKFKSIKETSVEVEWDPLDIAFE 
TWEIIFRNMNKEDEGEITKSLRRPETSYRQTGLAPGQEYEISLHIVKNNTRGPGLKKV 
TTTRLDAPSQIEVRDITDTTALITWSKPLAEIDSIELSYGIKDVPGDRTTIDLTHEDN 
QYSIGNLKPDTEYEVSLISRRVDMASNPAKETFITGLDAPRNLRRVSQTDNSITLEWR 
NVKADIDSYRIKYAPISGGDHAEIDVPKSQQATTKTTLTGLRPGTEYGVGVSAVKGDK 
EGDPATINAATEIDAPRDLQVSETTQDSLTLFWKTPLAKFDRYRLNYSLPTGQSIEIQ 
LPKDATSHVLTDLEPGQEYTVLLTAEKGRHKSKPARVKASTEEVPSLENLTVTEAGWD 
GLRLNWTADDLAYEYFVIQVQEANKVETAHNFTVLGNLRTADIPGLKAATPYRVSIYG 
VARGYKTPVLSAETFTGKTPSLGEVTVAEVGWDALKLNWTAPEGAYTNFFIQVLEADM 
TQTVQNLTVPGGLRSVDLPGLKAATRYYITVRGVTQDFSTAPLSVEVLTEEIPQLGGL 
SVTEVSWDSLTLNWTTDDLAYKHFIIQVQEANNVEAAQNLTVSGSLRVVDIPGLKADT 
PYRVSIYGVIQGYRTPMLSADVSTAKEPEIGNLNISDVTPESFNLSWTATDGIFDMFT 
IEIIDSNRLLQTAEHNISGAERTAHISGLPPSTDFIVYLSGIAPSIRTKTISTTATTE 
AEPEVDNLLVSDATPDGFCLSWTADEGIFDSFVIRIRDTKKQSEPQEITLPSPDRTRD 
ITGLREATEYEIELYGISRGRRSQPVSAIATTAMGSPKEIMFSDITENAATVSWRAPT 
AQVESFRITYVPVTGGPPSMVTVDGTDTETRLVRLTPGVEYHVSVIAMKGFEESDPVS 
GSLITALDGPSGLLTANITDSEALAMWQPAIATVDSYVISYTGERVPEITRTVSGNTV 
EFELHDLEPATEYTLSVFAEKGHQKSSTIATKFTTDLDSPRELTATEVQSETAFLTWR 
PPRASVTGYLLVYESVDGTVKEVIVGPDTTSYSLADLSPSTHYTARIQALSGSLRSKL 
IQTIFTTIGLLYPFPRDCSQAMLNGDTTSGLYTIYINGDKTQALEVYCDMTSDGGGWI 
VFLRRKNGREDFYRNWKAYATGFGDRREEFWLGLDNLSKITAQGQYELRVDLQDHGES 
AYAVYDRFSVGDAKSRYKLKVEGYSGTAGDSMNYHNGRSFSTYDKDTDSAITNCALSY 
KGAFWYKNCHRVNLMGRYGDNNHSQGVNWFHWKGHEYSIQFAEMKLRPSNFRNLEGRR 
KRA 
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